Photo of Clinical Research Volunteers
Office of the Vice President for Research
FindAStudy :: Human Studies @ UTHSCSA
212  Studies 102  Researchers 27  Categories
× Server Error: Please contact a VPR IT team member for assistance.
× Result: 0 studies found using ""
No studies found - try again with different search terms.
Choose a Category Below to Show a List of Study Titles
  •   Aging and Geriatric

    •   Effect of mTOR Inhibition and other Metabolism Modulating Interventions on...
      Protocol No.
      HSC20120304H
      Official Title
      Effect of mTOR Inhibition and other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Fuctional Consequences.
      Description
      A research study of the mechanisms that are affected by the mTOR inhibition by Rapamycin. Rapamycin is a drug approved by the US Food and Drug Administration (FDA) for human use that has shown to increase lifespan in laboratory animals. In human medicine, Rapamycin is used is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. mTOR controls growth of cells in your body. Rapamycin reduced mTOR effects. The researchers hope to learn how mTOR inhibition affects humans by looking at how the immune system that is altered in normal aging and mTOR inhibition by Rapamycin. The information gained from these experiments will aid in understanding how mTOR inhibition works in humans and will provide new and important information on changes in age-related immune system regulation.
      Contact
      210-497-7279
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Human Innate Immunity and Tuberculosis
      Protocol No.
      HSC20170315H
      Official Title
      Human Innate Immunity and Tuberculosis
      Description
      Tuberculosis is an infection that primarily affects the lungs and causes fever and weight loss. While some people exposed to the tuberculosis (TB) bacteria develop the disease others do not. An important step in our understanding of these different responses is to measure the response of immune cells to infection with the TB bacteria. This study will request blood to be collected from healthy individuals and individuals who have had a positive test result for TB.
      Contact
      (210) 258-9577
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Illness representations in elders living in the United States with Multiple...
      Protocol No.
      HSC20160103H
      Official Title
      Illness Representations in Elders Living in the United States with Multiple Chronic Conditions: A Mixed Methods Study
      Description
      Multiple Chronic Conditions (MCC) are two or more long-lasting conditions that may be controlled but not cured. Illness representation (IL) is how a person feels about and manages their chronic condition. Coping procedures are actions taken to manage a condition and appraisal represents the evaluation of how one manages their condition. Understanding IL,coping procedures and appraisals may help to improve management of multiple chronic conditions.
      Contact
      210-291-7358
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Long-Term Nicotine Treatment of Mild Cognitive Impairment
      Protocol No.
      HSC20180378H
      Official Title
      Long-Term Nicotine Treatment of Mild Cognitive Impairment
      Description
      Long-Term Nicotine Treatment of Mild Cognitive Impairment There is some evidence that nicotine interacts with the brain cells involved in memory and attention. Difficulty in these areas can be symptoms of Mild Cognitive Impairment (MCI). This clinical trial seeks to enroll individuals with MCI to determine if nicotine, delivered via patch, is helpful in improving memory when compared to placebo. The Biggs Institute is one of several sites enrolling participants in this study. Eligible participants will be between 55-90 years old, with mild memory problems, that they, their loved one, or a doctor have noticed. Participants will need to identify a study partner who can come to every clinic visit with them. Interested individuals must speak English fluently, and have no history of tobacco or nicotine use within the last year.
      Contact
      210-567-8229
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Metformin and vaccine response in older adults
      Protocol No.
      HSC20180171H
      Official Title
      Metformin and vaccine response in older adults
      Description
      Older adults’ immune systems will weaken with age. Over time, it becomes more difficult to mount an adequate immune response to vaccines to protect against subsequent infections, such as pneumonia. This study will provide information on whether a treatment with metformin will improve ‘pneumonia’ vaccine responses in older adults. Participants will be followed for 3 months.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   NF-Kappa B Activation by NADPH Oxidases (Project of a program entitled...
      Protocol No.
      HSC19949484H
      Official Title
      NF-Kappa B Activation by NADPH Oxidases (Project of a program entitled "Nuclear Factor Kappa B, Oxidative Stress and Aging)
      Description
      This study is a research project on the antibacterial function of white blood cells. We hope to learn how white blood cells work to prevent infection and how they respond after infection occurs.
      Contact
      210-562-4010
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study...
      Protocol No.
      HSC20170199H
      Official Title
      Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study in idiopathic pulmonary fibrosis
      Description
      To reduce the abundance of pro-inflammatory cells over baseline within subjects following treatment with dasatinib and quercetin
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Using Metformin to Prevent Frailty in Older Patients who have Pre-Diabetes
      Protocol No.
      HSC20150237H
      Official Title
      Metformin for Preventing Frailty in High-risk Older Adults
      Description
      Many older adults will become frail with age. Older adults with pre-diabetes are at the highest risk of becoming frail. This study will provide information on whether treatment with metformin will delay or prevent the onset of frailty. Participants will be followed for two years.
      Contact
      210-617-5190
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Behaviors and Mental Disorders

    •   A Comparison of Web-Prolonged Exposure and Present-Centered Therapy for PTSD
      Protocol No.
      HSC20150392H
      Official Title
      A Comparison of Web-Prolonged Exposure (Web-PE) and Present-Centered Therapy for PTSD among Active-Duty Military Personnel and Veterans: Efficacy and Biological Mechanisms
      Description
      This STRONG STAR study evaluates how 10 sessions of an internet-delivered treatment, Web-PE, compare to 10 sessions of a therapist-delivered treatment, PCT in the treatment of PTSD. The project will also evaluate if changes in PTSD symptoms are linked to changes in stress hormones. Eligible participants are active duty military personnel with PTSD who have deployed since 9/11 and who are stationed at Fort Hood, Texas.
      Contact
      254-449-3617
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   A Pilot Study of the Treatment for Trauma-Related Nightmares
      Protocol No.
      HSC20150396H
      Official Title
      A Pilot Randomized Controlled Trial of Treatment for Trauma-Related Nightmares In Active Duty Military Personnel
      Description
      The researchers hope to learn if a behavioral treatment for nightmares can significantly reduce nightmare frequency, nightmare severity, sleep problems, depression and anxiety in active duty military personnel. Eligible participants are active duty military personnel with Nightmare Disorder who are stationed at Fort Hood, Texas.
      Contact
      254-288-1360
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   A study of a new medicine for the treatment of...
      Protocol No.
      HSC20170700H
      Official Title
      A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Safety, and Efficacy Study of SHP465 in Children Aged 6-12 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)
      Description
      Children aged 6 to 12 years of age will have an evaluation to determine if they have ADHD. They then will be selected at random (like a flip of a coin) to either receive a medicine for ADHD (SHP465) or a placebo (an empty pill) for four weeks.
      Contact
      210-450-8405
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   A study of a new medicine for the treatment of...
      Protocol No.
      HSC20170701H
      Official Title
      A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactivity Disorder
      Description
      Children aged 4 to 12 years of age will have an evaluation to determine if they have ADHD. This study will be using an investigational drug (SHP465) for the treatment of ADHD. Participation in this study will last about 52 weeks.
      Contact
      210-450-8405
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   An Open-Trial of Web-Prolonged Exposure (Web-PE) among Active-Duty Military...
      Protocol No.
      HSC20170600H
      Official Title
      An Open-Trial of Web-Prolonged Exposure (Web-PE) among Active-Duty Military Personnel and Veterans
      Description
      The purpose of this study is to improve access to treatment for posttraumatic stress disorder (PTSD) by evaluating whether 10 sessions of PE delivered via the Internet over 8 weeks (Web-PE) is effective in reducing PTSD symptoms. Eligible participants are active duty military personnel and veterans with PTSD who have deployed since 9/11. www.clinicaltrials.gov search "NCT03337750"
      Contact
      254-245-9743
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Brief treatment for Posttraumatic Stress Disorder: Enhancing treatment...
      Protocol No.
      HSC20150904H
      Official Title
      Brief Treatment for Posttraumatic Stress Disorder: Enhancing Treatment Engagement and Retention
      Description
      The purpose of this study is to investigate whether a brief written treatment for PTSD is equally effective as a more intensive treatment. Written Exposure Therapy (WET) is a brief, trauma-focused treatment that involves writing about your traumatic experiences. Cognitive Processing Therapy (CPT) is a more intensive, trauma-focused treatment that involves learning to recognize and challenge thoughts related to your traumatic experiences. Eligible participants are active duty military presonnel with PTSD who have deployed since 9/11 and who are stationed in the San Antonio area.
      Contact
      210-562-6726
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for...
      Protocol No.
      HSC20140055H
      Official Title
      Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for Combat-Related PTSD
      Description
      This STRONG STAR research study will examine effective ways of delivering Cognitive Processing Therapy (CPT) for combat-related posttraumatic stress disorder (PTSD). CPT involves learning to recognize and challenge thoughts related to a traumatic experience and is typically done through face-to-face sessions in a mental health clinic. However, traveling into a clinic can be a potential barrier for some people. The goal of this study is to evaluate the effectiveness of administering CPT in one of the following treatment settings: 1) face-to-face in a clinic office, 2) face-to-face in the home setting, or 3) through telehealth (i.e., video sessions on your computer) in the home setting. Eligible participants are OIF/OEF/OND veterans with PTSD who reside in the San Antonio area.
      Contact
      210-562-6727
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Cognitive-Behavioral Therapy for Posttraumatic Headache
      Protocol No.
      HSC20140339H
      Official Title
      CAP - Consortium to Alleviate PTSD - STVHCS Project 7 entitled -Randomized Clinical Trial of Cognitive-Behavior Therapy for Posttraumatic Headache-
      Description
      This study will evaluate whether a leading cognitive behavioral therapy for migraine headaches is effective with posttraumatic headaches (PTHA) for those who also have symptoms of posttraumatic stress (PTS) or posttraumatic stress disorder (PTSD). Investigators also seek to determine if treatment for PTHA also alleviates symptoms of PTS/PTSD, and whether treatment for PTS/PTSD might also alleviate headache symptoms. Eligible participants are OIF/OEF/OND veterans with posttraumatic headache following a head injury and co-occurring symptoms of PTS/PTSD who reside in the San Antonio area.
      Contact
      210-562-6737
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Functional neuroanatomy of social and perceived internal threat in anxious...
      Protocol No.
      HSC20170149H
      Official Title
      Functional neuroanatomy of social and perceived internal threat in anxious youth at high-risk for bipolar disorder
      Description
      We are looking for children ages 8-17 who are anxious or worry a lot AND who have a biological parent with Bipolar Disorder. We are also looking for healthy families in which the parents and child have not received psychiatric diagnoses. Mental health assessments and MRI will be completed.
      Contact
      210-450-8362
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genetic and Environmental Influences on Growth, Motor, Cognitive, Behavioral...
      Protocol No.
      HSC20090012H
      Official Title
      Genetic and Environmental Influences on Growth, Motor, Cognitive, Behavioral and Language Development of Premature Infants
      Description
      A research study to understand how genes and the environment affect premature birth and infant development.
      Contact
      210-567-5225
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Identifying and Validating Complex Comorbidity Clusters in OEF-OIF Veterans
      Protocol No.
      HSC20100395H
      Official Title
      Trajectories of Resilience and Comorbidity Clusters in OEF-OIF Veterans (TRACC) Traumatic Brain Injury (TBI)
      Description
      The purpose of this study is to examine the kinds of health conditions that occur together (comorbidity clusters) in Veterans of wars in Afghanistan and Iraq (OEF/OIF) over time, and the types of experiences during military service and after military service that may be associated with these patterns.
      Contact
      210-617-5314
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Improvements in Brain Function during Psychotherapy For Teens with Symptoms...
      Protocol No.
      HSC20160637H
      Official Title
      Improvements in Brain Function during Psychotherapy For Teens with Posttraumatic Stress
      Description
      The purpose of the study is to analyze how brain functioning improves when symptoms of posttraumatic stress improve during psychotherapy. Teens who have experienced trauma and are bothered by symptoms of stress will be provided with the ‘gold-standard’ psychotherapy for trauma, at no-cost. They will have brain scans using Magnetic Resonance Imaging (MRI) before, during, and after the treatment: a total of 4 brain scans over the 20-week treatment. MRI is safe and does not use radiation or injections.
      Contact
      210-567-8162
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Maternal Opioid Morbidity Study (MOMS)
      Protocol No.
      HSC20160688H
      Official Title
      Maternal Opioid Morbidity Study (MOMS)
      Description
      Overdose by “ingestion of drugs” is the second leading cause of maternal mortality in the state of Texas. Maternal mortality is defined by the Centers for Disease Control and Prevention as a death occurring during pregnancy or within the first 365 days following the end of a pregnancy. Maternal overdose death in Texas is second only to maternal deaths caused by a cardiac event. Case records (including postmortem toxicology and police reports) indicate that most of these deaths involve the use of licit or illicit prescription opioids; however, little is known about the context of maternal overdose death. Therefore, we are recruiting women who have experienced an opioid use relapse and/or overdose as well as family members, friends and the significant others of women who died of a maternal overdose. We will be conducting private interviews and small group discussions to gain more insight into the circumstances that contribute to maternal overdose.
      Contact
      210-450-8161
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   MYRIAD
      Protocol No.
      HSC20160051H
      Official Title
      A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting with a Major Depressive Episode
      Description
      This research study is to investigate whether a blood test that measures blood proteins can correctly diagnose whether a depressed person has bipolar I disorder, bipolar II disorder, or major depressive disorder.
      Contact
      210-567-0780
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Project Remission: Maximizing Outcomes with Intensive Treatments for...
      Protocol No.
      HSC20160422H
      Official Title
      Project Remission: Maximizing Outcomes with Intensive Treatments for Combat-Related PTSD
      Description
      The purpose of this study is to examine whether 15 sessions of Massed-Prolonged Exposure (Massed-PE) delivered over 3-weeks is as effective as 15 days of an Intensive Outpatient Prolonged Exposure protocol (IOP-PE) delivered over 3-weeks in the treatment of combat-related PTSD. The researchers hope to learn if these programs improve treatment accessibility, patient retention, and treatment outcomes. Eligible participants are veterans and active duty military personnel with PTSD who have deployment since 9/11 and who are stationed in the San Antonio, Fort Hood, and Waco, Texas areas.
      Contact
      210-562-6726
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Social Support in Women Using Opioids During Pregnancy
      Protocol No.
      HSC20170018H
      Official Title
      Social Support, Stress, and Depressive Symptoms in Opioid Using Pregnant Women: A Mixed Methods Study
      Description
      The use of opioids during pregnancy is on the rise, placing pregnant women at risk for negative outcomes. The purpose of this the study is to measure social support, stress, and look at mental health outcomes of women using opioids during their pregnancy
      Contact
      (210) 450-8161
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Treatment of Comorbid Sleep Disorders and PTSD
      Protocol No.
      HSC20150900H
      Official Title
      Treatment of Comorbid Sleep Disorders and PTSD
      Description
      The researchers hope to learn if Cognitive-Behavioral Therapy of insomnia and nightmares and Cognitive Processing Therapy (CPT) of PTSD will reduce PTSD, and also result in improvements in other areas commonly affected by sleep disorders and PTSD. Eligible participants are Active duty military and recently discharged Veterans at Fort Hood’s Carl R. Darnall Army Medical Center (CRDAMC).
      Contact
      254-288-1360
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Understanding the genetics of bipolar I disorder in adolescents
      Protocol No.
      HSC20150334H
      Official Title
      Application of induced pluripotent stem cells for the study of bipolar I disorder
      Description
      The purpose of this research is to develop a cell-based system to study adolescent bipolar I disorder to better understand genetic and epigenetic mechanisms associated with risk and develop new methods for treatment. We will perform MRI, neurocognitive and neuropsychiatric testing and draw blood.
      Contact
      210-258-9766
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Cancers and Other Neoplasms

    •   Bones and joints

      •   AOST1321 - Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK...
        Protocol No.
        HSC20160209X
        Official Title
        AOST1321 - Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma. An Intergroup NCTN Phase 2 Study (CTMS# 16-0051)
        Description
        Primary Aims 1.1.1 To determine whether denosumab therapy either increases the disease control rate at 4 months in patients with recurrent measurable osteosarcoma as compared to historical COG experience or denosumab therapy produces an objective response rate greater than 5% (Cohort 1). 1.1.2 To determine whether denosumab therapy increases the disease control rate at 12 months in patients with recurrent resected osteosarcoma as compared to historical COG experience (Cohort 2). Secondary Aims 1.2.1 To investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of denosumab in subjects with recurrent osteosarcoma. 1.2.2 To describe the tolerability of denosumab in subjects with recurrent osteosarcoma. 1.2.3 To report the disease control rate and objective response rate for patients with recurrent osteosarcoma limited to bone. 1.2.4 To investigate biological markers potentially associated with response to denosumab in patients with recurrent osteosarcoma.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AOST1421, A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside...
        Protocol No.
        HSC20160053XT
        Official Title
        AOST1421, A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC#764038, IND# 4308) in Combination with GM-CSF in Patients with Recurrent Osteosarcoma (CTMS# 16-0013)
        Description
        1.1 Primary Aims To determine the disease control rate in patients with completely resected recurrent osteosarcoma treated with ch14.18 (dinutuximab) in combination with sargramostim (GM-CSF) as compared to historical COG experience. 1.2 Secondary Aims 1.2.1 To characterize the pharmacokinetics of ch14.18 (dinutuximab) in patients with recurrent osteosarcoma in the proposed administration schedule. 1.2.2 To determine the occurrence of unacceptable toxicity (UT) in patients with recurrent osteosarcoma treated with ch14.18 (dinutuximab) in combination with sargramostim. 1.3 Exploratory Aims 1.3.1 To assess the relationship between probability of disease control and tumor GD2 expression. 1.3.2 To attempt banking of tumor samples for future research studies from patients enrolled on the study who undergo biopsy or resection of suspected metastatic disease recurrence while on protocol therapy or during the evaluation period. 1.3.3 To assess KIR and FcyR genotypes NKp30 isoforms and its circulating ligand, B7-H6 and their relationships to the probability of disease control. 1.3.4 To determine a descriptive profile of human anti-chimeric antibody (HACA) during immunotherapy.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Brain & Nervous System

      •   A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum...
        Protocol No.
        HSC20140450X
        Official Title
        A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes (RNL) in Recurrent Glioblastoma (CTRC# 12-02)
        Description
        While radiation is an essential component to the treatment of glioblastoma, it''s use is limited due to toxicity when higher doses are attempted. Rhenium is a compound which releases radiation in small particles that are absorbed after only a fraction of an inch. This limited penetration means that high doses potentially can be given without the toxicity of other forms of radiation. In order for the radiation to be retained within the tumor, it has been packaged in microscopic fat-like particles termed nanoliposomes. These facilitate the uptake of the radiation particles by the tumor. In order to better characterize this form of radiation therapy, it is being administered in patients who have failed other forms of therapy for glioblastoma. The treatment is administered by tubing inserted into the center of the tumor in the operating room. There are two portions to this study. The first involves progressively increasing doses until the most tolerable dose can be identified. The second portion of the study involves a larger number of patients being treated at the determined most tolerable dose to better evaluate how well the treatment works.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety...
        Protocol No.
        HSC20170090HU
        Official Title
        A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB-2640 in Combination with Bevacizumab in Patients with First Relapse of High Grade Astrocytoma (CTMS# 16-0136)
        Description
        Primary Objective(s): To determine if the progression-free survival of patients with High Grade Astrocytoma who are treated with TVB-2640 in combination with bevacizumab is superior to treatment with bevacizumab alone. Secondary Objective(s): To evaluate the safety of TVB-2640 in combination with bevacizumab in patients with High Grade Astrocytoma. Exploratory Objective: To determine the extent by which TVB-2640 is able to penetrate the blood brain barrier where it might have the opportunity to affect tumor tissue metabolism.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACCL10P1 - Computerized Cognitive Training for Pediatric Brain Tumor...
        Protocol No.
        HSC20140435X
        Official Title
        ACCL10P1 - Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study A Limited-Institution Pilot Study (CTRC# 13-0061)
        Description
        This randomized clinical trial studies how well an adaptive computerized cognitive training program works compared to a non-adaptive computerized cognitive training program in treating younger patients with brain tumor who underwent radiation therapy. Providing a computer training program may improve the well-being and quality of life of patients with cognitive (physical and mental) function difficulties caused by radiation therapy to the brain.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACNS02B3: A CHILDREN''S ONCOLOGY GROUP PROTOCOL FOR COLLECTING AND BANKING...
        Protocol No.
        HSC20040266H
        Official Title
        ACNS02B3: A CHILDREN''S ONCOLOGY GROUP PROTOCOL FOR COLLECTING AND BANKING PEDIATRIC BRAIN TUMOR RESEARCH SPECIMENS
        Description
        he purpose of this study is to collect and store brain tissue samples and blood from children with brain cancer that will be tested in the laboratory. Collecting and storing samples of tumor tissue and blood from patients to test in the laboratory may help the study of cancer in the future.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in...
        Protocol No.
        HSC20110258X
        Official Title
        ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years (CTRC HSC20110258X)
        Description
        This randomized phase III trial is studying maintenance chemotherapy to see how well it works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma. Drugs used in chemotherapy, such as vincristine sulfate, carboplatin, cyclophosphamide, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving chemotherapy with radiation therapy may kill more tumor cells and allow doctors to save the part of the body where the cancer started.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACNS1123 : Phase 2 Trial of Response-Based Radiation Therapy for Patients...
        Protocol No.
        HSC20130346X
        Official Title
        ACNS1123 : Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) (CTRC# 12-0076)
        Description
        Drugs used as chemotherapy, such as carboplatin, etoposide, and ifosfamide work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x rays to kill tumor cells. Giving chemotherapy with radiation therapy may kill more tumor cells. This phase II trial studies how well chemotherapy and radiation therapy work in treating younger patients with newly diagnosed central nervous system germ cell tumors.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ALTE07C1 Neuropsychological, Social, Emotional, and Behavioral Outcomes in...
        Protocol No.
        HSC20090042X
        Official Title
        ALTE07C1 Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer (CTRC 20090042H)
        Description
        This research trial studies neuropsychological (learning, remembering or thinking) and behavioral testing in younger patients with cancer. Collecting information over time from a series of tests may help doctors develop effective tests to measure neuropsychological and behavioral function of patients with cancer. Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery testing at 9, 30, and 60 months post-diagnosis in a 1-hour session conducted by a neuropsychologist or psychologist. The Battery consists of tests of intelligence, processing speed/attention, memory, language preference, general developmental progress, attention and behavior/social/emotional function, executive function, adoptive function, and quality of life. Additionally, parents complete a parent-report questionnaire to gather information about patient''s function in terms of attention, memory, executive abilities, and behavioral, social, and emotional adaption.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Open-Label Non-Randomized, Multi-Center Phase-2 Study of...
        Protocol No.
        HSC20160689HU
        Official Title
        An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Glioblastoma at First Recurrence or Progression (CTMS# 16-0088)
        Description
        Primary To determine the objective response rate (ORR) per iRANO criteria following intra- and peritumoral infusion using CED of MDNA55 in adult subjects with GB at first recurrence following standard therapy Secondary To assess the safety of MDNA55 following CED in adult subjects with GB at first recurrence following standard therapy. To assess overall survival (OS) in these subjects To assess progression-free survival (PFS; using iRANO criteria) in these subjects Exploratory To assess the pharmacokinetics (PK) of MDNA55 in peripheral plasma as measured by enzyme-linked immunosorbent assay (ELISA) To assess anti-MDNA55 antibody titer and, if anti-MDNA55 titer is observed, determine neutralizing antibody titer and its effect on the safety and efficacy of MDNA55 To perform additional ad hoc efficacy and safety analyses as needed based on the data acquired in this study
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   COG ANBL00B1: Neuroblastoma Biology Studies
        Protocol No.
        HSC20010176X
        Official Title
        COG ANBL00B1: Neuroblastoma Biology Studies
        Description
        This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early...
        Protocol No.
        HSC20170313HU
        Official Title
        EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma (CTMS# 17-0041)
        Description
        Primary Aims To determine whether binary changes (increase vs. decrease) in normalized rCBV within enhancing tumor from baseline to 2 weeks after initiation of anti-angiogenic therapy is associated with overall survival (OS).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   PHASE III TRIAL OF OBSERVATION VERSUS IRRADIATION FOR A GROSS TOTALLY...
        Protocol No.
        HSC20180145X
        Official Title
        PHASE III TRIAL OF OBSERVATION VERSUS IRRADIATION FOR A GROSS TOTALLY RESECTED GRADE II MENINGIOMA (CTMS# 18-0016)
        Description
        The primary endpoint is progression-free survival (PFS). The principle objective is to determine the extent of clinical benefit of the addition of adjuvant radiotherapy (RT) to gross total resection (GTR) for patients with newly diagnosed World Health Organization (WHO) grade II meningioma.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Breast

      •   A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3...
        Protocol No.
        HSC20150602HU
        Official Title
        A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects (CTMS# 15-2100)
        Description
        Primary Objectives Assess the impact of dietary (omega 3 FFA) or pharmacological (ASA) COX-2 inhibitors on: patient serum-induced expression of PGE2 and aromatase by neoplastic mammary epithelial cells circulating levels of pro-inflammatory cytokines (i.e. IL-6, TNF- , IGF-1), steroids (i.e. estrogen and testosterone) and lipids (omega-6 and omega-3 PUFAs) Secondary Objectives Correlation for body mass index impact on response to COX2 inhibition.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3...
        Protocol No.
        HSC20160665HU
        Official Title
        A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Free Fatty Acid Supplementation on Breast Cancer (CTMS# 16-0119)
        Description
        Primary Objectives Assess the impact of dietary omega 3 FFA: Serum CSF-1 levels patient serum-induced expression of PGE2 by neoplastic mammary epithelial cells, OM3/OM6 circulating levels of pro-inflammatory cytokines (i.e. IL-6, TNF- , IGF-1), steroids (i.e. estrogen and testosterone) and lipids (omega-6 and omega-3 PUFAs) Secondary Objectives Tissue expression of aromatase, CSF1/CSF1R and infiltrating macrophage number and polarity.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic...
        Protocol No.
        HSC20160122HU
        Official Title
        A Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC (CTMS# 16-0003)
        Description
        Primary Objective To evaluate the Objective Response Rate (ORR) of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) Secondary Objectives To assess the safety and tolerability of poziotinib in patients with HER2-positive MBC To evaluate other efficacy variables of poziotinib in patients with HER2-positive MBC, including the following: Progression-Free Survival (PFS) Disease Control Rate (DCR) Overall Survival (OS) Time to Progression (TTP)
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase II, Multicenter, Open-Label, Two-Cohort, Noncomparative Study to...
        Protocol No.
        HSC20170301HU
        Official Title
        A Phase II, Multicenter, Open-Label, Two-Cohort, Noncomparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients with PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-Negative Advanced Breast Cancer (aBC), Who Have Progressed On or After CDK 4/6 Inhibitor Treatment (CTMS# 17-0049)
        Description
        Primary Outcome Measures: The percentage of patients who are alive without disease progression Assess the percentage of patients without disease progression based on local investigator assessment per RECIST in cohort A and cohort B
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A PILOT STUDY OF HYDROXYTYROSOL, A COMPONENT OF OLIVE OIL FOR BREAST CANCER...
        Protocol No.
        HSC20160660HU
        Official Title
        A PILOT STUDY OF HYDROXYTYROSOL, A COMPONENT OF OLIVE OIL FOR BREAST CANCER PREVENTION IN WOMEN AT HIGH RISK OF BREAST CANCER (CTMS# 16-0068)
        Description
        Primary To conduct a pilot breast cancer prevention study of hydroxytyrosol in women at increased risk of breast cancer. To assess whether mammographic density is reduced in pre or post menopausal women at high risk of breast cancer taking hydroxytyrosol for 1 year compared with baseline. Secondary To assess the toxicity of hydroxytyrosol
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Pre-surgical Clinical Trial of Therapy with S-equol in Women with Triple...
        Protocol No.
        HSC20150231H
        Official Title
        A Pre-surgical Clinical Trial of Therapy with S-equol in Women with Triple Negative Breast Cancer (CTMS# 14-2018)
        Description
        After a baseline breast tumor core biopsy, eligible women with triple negative breast cancer (ER- alpha, PR and HER-2 receptor negative) will be treated with S-equol at a dose of 50 mg twice daily for a period of about 14 days (10-21 day range). After completion of treatment, a second breast tumor sample will be obtained to compare molecular changes between the two specimens. The second pathology specimen may be from the surgical resection of the breast tumor, or a repeat core needle biopsy, if no further surgery is planned. The primary endpoint will be the absolute change in the Ki67, which is a validated marker of tumor proliferation in breast cancer. Secondary endpoints will include assessment of total ER-beta and pY36 levels as measured by immunohistochemical staining and their correlation with S-equol effects. Further treatment after surgical resection or second core needle biopsy of the tumor will be guided by tumor size, nodal status and other standard parameters, and is at the discretion of the treating physician. The Investigator hypothesizes that S-equol will cause a measurable decrease in Ki-67 in estrogen receptor beta expressing triple negative breast cancers, indicating its potential efficacy in this tumor type.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs....
        Protocol No.
        HSC20170532HU
        Official Title
        A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0) (CTMS# 17-0048)
        Description
        Primary Objective Non-inferiority of partial breast irradiation (PBI) and concurrent compared to sequential chemotherapy with respect to acute grade 3-4 radiation toxicity.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A study attempting to improve the comfort during screening mammography...
        Protocol No.
        HSC20160392HU
        Official Title
        A study attempting to improve the comfort during screening mammography (CTMS# 16-0045)
        Description
        To determine in a randomized trial whether it is possible to decrease the discomfort and anxiety of mammography by using the local analgesic lidocaine, or by using calming music in patients receiving a mammogram.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Aging mammary stem cells and breast cancer prevention (CTMS# 15-2096)
        Protocol No.
        HSC20150556HU
        Official Title
        Aging mammary stem cells and breast cancer prevention (CTMS# 15-2096)
        Description
        To examine whether aging increases human mammary stem/progenitor cells (MaSC) with aberrant phenotypes and if rapamycin can reduce malignant markers and MaSC number in surgical specimens.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Alliance A011401 Randomized Phase III Trial Evaluating the Role of Weight...
        Protocol No.
        HSC20160530XT
        Official Title
        Alliance A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (CTMS# 16-0082)
        Description
        Primary Objective To compare the effect of a supervised weight loss intervention plus health education materials versus health education materials alone upon invasive disease free survival (iDFS) in overweight (BMI 27-29.9 kg/m2) and obese (BMI 30kg/m2) women diagnosed with HER-2 negative, stage II and III breast cancer. Secondary Objectives To determine the relationship between changes in weight and iDFS, and to explore interaction between the level of clinical benefit from weight loss and the intervention. To evaluate the effect of a supervised weight loss intervention upon: a) Overall survival b) Distant disease free survival c) Weight d) Body composition (as measured by waist and hip circumference) e) Insulin Resistance Syndrome associated conditions diabetes, hospitalization for CV disease To determine the impact of a supervised weight loss intervention on IDFS within subgroups of women with 1) hormone receptor positive breast cancer and 2) hormone receptor negative breast cancer. To determine the impact of a supervised weight loss intervention on IDFS within subgroups of 1) premenopausal women and 2) post-menopausal women.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Clinical trial to study the efficacy and safety of Eribulin Mesylate taken...
        Protocol No.
        HSC20150568HU
        Official Title
        An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination with Pembrolizumab in Subjects with Metastatic Triple-Negative Breast Cancer (mTNBC) (CTMS# 15-2079)
        Description
        Primary Objectives For the Phase 1b part to determine safety and tolerability of eribulin mesylate in combination with pembrolizumab in subjects with metastatic triple-negative breast cancer previously treated with 0 to 2 lines of chemotherapy in the metastatic setting. For the Phase 2 part to evaluate objective response rate, based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, of eribulin mesylate in combination with pembrolizumab in subjects with metastatic triple-negative breast cancer previously treated with 0 to 2 lines of chemotherapy in the metastatic setting. Secondary Objectives To evaluate Progression-Free Survival (PFS) To evaluate Overall Survival (OS) To evaluate Duration of Response (DOR) To evaluate efficacy in a subset defined by PD-L1 (programmed death receptor-ligand 1) expression. To evaluate the safety and tolerability Exploratory Objectives To evaluate Clinical Benefit Rate (CBR) To evaluate exposure-response relationship To explore potential effects of pembrolizumab co-administration on the pharmacokinetics (PK) of eribulin mesylate To explore ORR, PFS, DOR, and CBR using the immune-related response criteria in solid tumors (irRECIST)
        Contact
        410-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With...
        Protocol No.
        HSC20150697HU
        Official Title
        NRG-BR003, A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (CTMS# 15-2089)
        Description
        Primary Objective To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. Secondary Objectives To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the overall survival (OS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the breast cancer-free survival (BCFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the recurrence-free interval (RFI) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the distant recurrence-free interval (DRFI) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. To determine the toxicity of doxorubicin/cyclophosphamide followed by paclitaxel administered concurrently with carboplatin compared to the toxicity of doxorubicin/cyclophosphamide followed by paclitaxel alone. To determine if germline BRCA status is associated with benefit in IDFS or OS from the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel in patients with operable node-positive or high-risk node-negative triple-negative breast cancer. To determine if the addition of carboplatin will improve the RFI among the homologous recombination (HR) deficient patients as determined by the homologous recombination deficiency (HRD) score. To determine whether the efficacy of carboplatin on RFI in HR-deficient patients differs from that in patients who are not HR-deficient. To collect tissue and blood samples at several occasions for future biomarkers development in predicting risk of breast cancer recurrence in patients with operable node-positive or high-risk node-negative triple-negative breast cancer treated with doxorubicin/cyclophosphamide followed by paclitaxel with or without carboplatin and predicting benefit from the addition of carboplatin among these patients.
        Contact
        410-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced...
        Protocol No.
        HSC20170535HU
        Official Title
        Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy (CTMS# 17-0033)
        Description
        Specific Aims 1. Evaluate the safety profile and efficacy of cryotherapy in the prevention of peripheral neuropathy during treatment with taxane chemotherapy. 2. Evaluate the safety profile and efficacy of cryotherapy in the prevention of nail toxicity during treatment with taxane chemotherapy. 3. Evaluate the role of TRPA1 in CIPN in patients receiving taxane-based chemotherapy.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Factors influencing decision on prophylactic surgery in Hispanic high risk...
        Protocol No.
        HSC20170066HU
        Official Title
        Factors influencing decision on prophylactic surgery in Hispanic high risk breast cancer patients of South Texas and their health care providers (CTMS# 16-0095)
        Description
        Identify the factors that play a role in decision-making regarding RRPM in Hispanic women of GRACIAS Texas compared with non-Hispanic whites Assess the patient/provider communication regarding RRPM in South Texas Determine if differences in understanding and barriers to RRPM differ between Hispanic and Non-Hispanic white women.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to...
        Protocol No.
        HSC20170531XT
        Official Title
        MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) (CTMS# 17-0068)
        Description
        Primary Objectives Create a large scale, population-based registry of full genome expression data matched with clinical data to investigate new gene associations with prognostic and/or predictive value Utilize registry data to graduate identified expression signatures into subset trials and recommend interventional trials
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   NSABP B-51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy...
        Protocol No.
        HSC20150021X
        Official Title
        NSABP B-51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (CTRC14-0010)
        Description
        To evaluate whether the addition of chest wall + regional nodal radiation therapy (XRT) after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly reduce the rate of events for invasive breast cancer recurrence-free interval (IBC-RFI) in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.
        Contact
        210-450-5924
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs....
        Protocol No.
        HSC20160505HU
        Official Title
        Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (CTMS# 16-0014)
        Description
        Primary Objective To assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on bi-compartmental [both central nervous system (CNS) and non-CNS] progression-free survival (PFS) based on independent central review Secondary Objectives To assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on bi-compartmental PFS based on investigator assessment To assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on PFS, separately in the CNS and non-CNS compartments To assess the effects of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on time to CNS progression To assess the effects of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on objective response rate (ORR), separately in the CNS and non-CNS compartments To assess the duration of response of ONT-380 in combination with capecitabine and trastuzumab, separately in the CNS and non-CNS compartments To assess the clinical benefit rate (CBR) [stable disease (SD) for 6 months, or best response of complete response (CR) or partial response (PR)] of ONT-380 vs. placebo in combination with capecitabine and trastuzumab, separately in the CNS and non-CNS compartments To assess the effects of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on overall survival (OS) To assess the safety and tolerability of ONT-380 in combination with capecitabine and trastuzumab
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase IB/II Open-Label Single Arm Study to Evaluate Safety and Efficacy of...
        Protocol No.
        HSC20170753HU
        Official Title
        Phase IB/II Open-Label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination with Letrozole and Plabociclib in Subjects with Hormone Receptor Positive and HER2-Positive Metastatic Breast Cancer (CTMS# 17-0138)
        Description
        To evaluate safety and tolerability of tucatinib used in combination with palbociclib and letrozole, and to confirm that current RP2D of tucatinib and FDA approved dosing of palbociclib remain the same in the triplet combination
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1207 - Hormone Therapy With or Without Everolimus in Treating Patients with...
        Protocol No.
        HSC20140060X
        Official Title
        S1207, Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (CTRC# 13-0002)
        Description
        The purpose of this study is to determine whether adding a year of everolimus to standard adjuvant hormonal therapy improves disease-free interval in patients with hormone-receptor-positive and HER2-negative breast cancer. Eligible adult patients (either sex) have a diagnosis of breast cancer and have completed surgery, radiation therapy, and/or adjuvant or neoadjuvant chemotherapy and have no evidence of disease at time of study entry. Patients with inflammatory breast cancer or metastatic disease, serious cardiac disease, uncontrolled diabetes, hepatitis, uncontrolled pulmonary disease, or impaired gastrointestinal function are not eligible. Estimated Enrollment: 3500 patients from multiple cancer centers in the US.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1501, Prospective Evaluation of Carvedilol in Prevention of Cardiac...
        Protocol No.
        HSC20180058XT
        Official Title
        S1501, Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III (CTMS# 17-0124)
        Description
        To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab based HER-2 targeted therapy.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Cervix

      •   Cultural Barriers to Cervical Cancer Prevention among Hispanic Women (CTMS...
        Protocol No.
        HSC20160050H
        Official Title
        Cultural Barriers to Cervical Cancer Prevention among Hispanic Women (CTMS 15-2120)
        Description
        Aim 1: To identify the interactions of health literacy, culture and language as they relate to cervical cancer screening practices and behaviors among Hispanic women. Aim 2: To investigate the relationships between health literacy, demographic and social variables, sources of information and cervical cancer screening practices among Hispanic women.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Los Dones - Hispanic Men''s Health Literacy Related to their female...
        Protocol No.
        HSC20160049H
        Official Title
        Los Dones - Hispanic Men''s Health Literacy Related to their female counterparts cervical cancer prevention practices (CTMS 15-2121)
        Description
        To investigate the relationships between Hispanic men''s health literacy, demographic, social variable, sources of information, and their female counterpart cervical cancer prevention practices
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Colon

      •   A pilot study to evaluate the chemopreventive effects of epigallocatechin...
        Protocol No.
        HSC20160446HU
        Official Title
        A pilot study to evaluate the chemopreventive effects of epigallocatechin gallate (EGCG) in colorectal cancer (CRC) patients with curative resections (CTMS# 16-0085)
        Description
        To evaluate the preventive effects of EGCG on colonic tissue in patients with resected colorectal cancer when compared to patients on observation.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Modulation of Autophagy: A Clinical Study of Vorinostat plus...
        Protocol No.
        HSC20150178HU
        Official Title
        Modulation of Autophagy: A Clinical Study of Vorinostat plus Hydroxychloroquine versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)
        Description
        To determine the clinical efficacy with progression-free survival (PFS-1) of the combination of VOR plus HCQ when compared to RGF in treatment-refractory mCRC.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon...
        Protocol No.
        HSC20160555HU
        Official Title
        Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis (CTMS# 16-0101)
        Description
        This study will evaluate the expression of B7-H1 in human colon tissue, define B7-H1 signaling pathways in colon cells and test the ability of recombinant Listeria to modulate B7-H1 in human colonic tissues in vitro.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   SWOG S0820, Adenoma and Second Primary Colorectal Cancer Prevention Trial...
        Protocol No.
        HSC20130412H
        Official Title
        S0820 - A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) (CTRC#13-0036)
        Description
        The study is designed to investigate whether eflornithine, sulindac or both are effective in preventing or delaying adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer. The primary objective is to assess whether eflornithine and/or sulindac are effective in reducing the recurrence rate at 3 years. The study will enroll approximately 1340 participants from hundreds of cancer centers in the US. In addition to other conditions for enrollment, eligible patients have a history of stage 0-III colon cancer that was surgically removed up to 1 year previously; rectosigmoid cancers are eligible if no prior radiation therapy, no evidence of cancer by colonoscopy exam at time of study entry, and able to take oral medications. Patients who have a history of uncontrolled hypertension or gastric/duodenal ulcer within past year or other medical conditions may not be eligible to enroll.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Esophagus

      •   A Five Part, Phase 1, Multi-center, Open-label Study of DKN-01 in...
        Protocol No.
        HSC20140189H
        Official Title
        A Five Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part C: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal or Gastro-esophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Squamous Cell Cancer; Part E: An Expansion Cohort in Patients with Relapsed or Refractory Gastric Adenocarcinoma with Wnt Signaling Alterations (CTRC# 14-0002)
        Description
        A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel in participants with refractory/recurrent esophageal or gastro-esophageal junction cancer Part A is a Dose-Escalation Study in Participants with Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors. Part B is an Expansion Cohort in Participants with Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Hodgkin Lymphoma

      •   AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND...
        Protocol No.
        HSC20150884XT
        Official Title
        AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents (CTMS 15-2094)
        Description
        Primary Aims 1.1.1 To assess the event free survival (EFS) of a novel regimen incorporating brentuximab vedotin (Bv; AdcetrisTM) in the chemotherapy backbone of doxorubicin (Adriamycin), vincristine, etoposide, prednisone and cyclophosphamide (Bv-AVEPC) in newly diagnosed high-risk cHL compared to those treated with ABVE-PC. Secondary Aims 1.2.1 To determine whether children/adolescents with high-risk cHL treated with Bv-AVEPC have a higher rate of early response (determined by FDG-PET) and a reduction in response-directed radiation therapy (RT) compared to those treated with ABVE-PC. 1.2.2 To compare the rate of neuropathy (> Grade 3) among patients treated on the Bv-AVEPC (experimental arm) to patients treated on the ABVE-PC (standard arm). Exploratory Aims Childhood International Prognostic Score (CHIPS) 1.3.1 To validate and compare the Childhood Hodgkin International Prognostic Score (CHIPS) to conventional Ann Arbor Stage (Stages II B with bulk, III B, IV A or B) in predicting outcome in high-risk childhood cHL. Biology 1.3.2 To determine the incidence of preferentially expressed antigen in melanoma (PRAME) and testis-specific antigens in EBV- cHL tumors and the incidence of EBV antigens (EBNA1, LMP1, LMP2) in EBV+ cHL tumors, with the goal of developing strategies to integrate cellular therapy into treatment for newly diagnosed high-risk cHL. Imaging 1.3.3 To incorporate qualitative visual FDG-PET into response-directed treatment algorithms and explore quantitative FDG-PET and CT definitions of tumor burden and response for incorporation into next generation pediatric cHL risk-stratification schemes. Radiation Therapy 1.3.4 To evaluate the reduction in normal tissue irradiation associated with the current treatment approach compared to the volume of historic IFRT fields. 1.3.5 To evaluate EFS and patterns of relapse following protocol-specified RT utilization and treatment volumes. Patient Reported Outcomes (PRO) of Peripheral Neuropathy and Health-Related Quality of Life 1.3.6 To characterize the extent of chemotherapy induced peripheral neuropathy (CIPN), as reported by patients and parent proxies, through serial administration of the FACT-GOG-NTX. 1.3.7 To describe the Health-Related Quality of Life (HRQL) consequences of peripheral neuropathy over time by correlating total neuropathy scale scores with the individual items with the CHRIs-Global scale (e.g., physical health, pain, emotional functioning). 1.3.8 To perform a cross validation of the FACT-GOG-NTX with the TNS-PV to determine the performance of both measures with the use of brentuximab vedotin in a limited institutional approach in children and adolescents with cHL (See Appendix VII). Economic (For US Institutions Only) 1.3.9 To assess the resource use and cost implications of Bv in combination with chemotherapy and radiotherapy (RT) for newly diagnosed high-risk cHL in children and adolescents (See Appendix VIII).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Kidney

      •   A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of...
        Protocol No.
        HSC20170530XT
        Official Title
        A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) (CTMS# 17-0032)
        Description
        Primary Objective: To compare DFS as assessed by the investigator for participants treated with pembrolizumab versus those receiving placebo Hypothesis: Pembrolizumab is superior to placebo with respect to DFS. Secondary Objective: To compare OS for participants treated with pembrolizumab versus those receiving placebo Hypothesis: Pembrolizumab is superior to placebo with respect to OS
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AREN03B2 Renal Tumors Classification, Biology and Banking Study (CTRC 20070394X)
        Protocol No.
        HSC20070394X
        Official Title
        AREN03B2 Renal Tumors Classification, Biology and Banking Study (CTRC 20070394X)
        Description
        This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   EA8143, A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs....
        Protocol No.
        HSC20170129HU
        Official Title
        EA8143, A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) (CTMS# 16-0148)
        Description
        Primary Objectives To compare recurrence-free survival (RFS) between patients with locally advanced renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial nephrectomy with patients randomized to surgery alone. Secondary Objectives To evaluate for differences in recurrence-free survival associated with perioperative nivolumab compared to surgery alone among the subset of patients with clear cell histology. To compare the overall survival between patients randomized to perioperative nivolumab in addition to resection to patients randomized to primary tumor resection alone. To describe the safety and tolerability of perioperative nivolumab
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Leukemia, other

      •   COG AALL05B1, A Children''s Oncology Group Protocol for Collecting and...
        Protocol No.
        HSC20070100X
        Official Title
        COG AALL05B1, A Children''s Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
        Description
        RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and help predict the recurrence of cancer. PURPOSE: This research study is collecting and storing samples of bone marrow and blood from patients with relapsed acute lymphoblastic leukemia or relapsed non-Hodgkin lymphoma.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Liver

      •   A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy...
        Protocol No.
        HSC20180193XT
        Official Title
        A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma (CTMS# 17-0105)
        Description
        Primary: To compare overall survival (OS) between BGB-A317 and sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC) To compare objective response rate (ORR) assessed by Blinded Independent Review Committee (BIRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 between BGB-A317 and sorafenib as first-line treatment in patients with unresectable HCC
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Hepatocellular Carcinoma Tissue Acquisition (CTMS# 15-2144)
        Protocol No.
        HSC20150834HU
        Official Title
        Hepatocellular Carcinoma Tissue Acquisition (CTMS# 15-2144)
        Description
        Obtain biopsy specimens from Hispanic patients with liver cancer when they come to Radiology clinic for ablation therapy
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Modulation of Sorafenib induced autophagy using hydroxychloroquine in...
        Protocol No.
        HSC20160515HU
        Official Title
        Modulation of Sorafenib induced autophagy using hydroxychloroquine in hepatocellular cancer (CTMS# 16-0076)
        Description
        Primary Objective(s): To determine the clinical efficacy with to determine the clinical efficacy with time to tumor progression (TTP) of the combination of HCQ and sorafenib in first line advanced HCC (cohort 1); and the addition of HCQ to sorafenib in patients who progress on sorafenib (cohort 2). Secondary Objective(s): To determine the overall survival in advanced HCC patients receiving HCQ and sorafenib in both cohort 1 and 2 To evaluate the tumor response rate in advanced HCC patients receiving HCQ and sorafenib To further define the safety in advanced HCC patients receiving HCQ and sorafenib To identify biomarkers of autophagy modulation and immune markers that correlate with clinical efficacy in advanced HCC patients receiving HCQ and sorafenib.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   The Texas Hepatocellular Carcinoma Consortium (CTMS# 16-0063)
        Protocol No.
        HSC20160274HU
        Official Title
        The Texas Hepatocellular Carcinoma Consortium (CTMS# 16-0063)
        Description
        The overarching goal of the Texas Hepatocellular Carcinoma Consortium (THCCC), funded by CPRIT Multiple Investigator Research Award (MIRA), is to reduce the burden and mortality of hepatocellular cancer (HCC) in Texas.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Treatment of Children with all Stages of Hepatoblastoma (CTRC# AHEP0731)
        Protocol No.
        HSC20100158X
        Official Title
        Treatment of Children with all Stages of Hepatoblastoma (CTRC# AHEP0731)
        Description
        This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs (cancer fighting medicines), and when necessary liver transplant are the main current treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best treatment. Treating patients according to the risk group they are in may help get rid of the cancer, keep it from coming back, and decrease the side effects of chemotherapy.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Lung

      •   A Phase III, Double-Blind, Randomized, Placebo-Controlled Multi-Centre,...
        Protocol No.
        HSC20180099XT
        Official Title
        A Phase III, Double-Blind, Randomized, Placebo-Controlled Multi-Centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients with Epidermal Growth Factor Mutation Positive Stage IB-IIIA Non-Small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) (CTMS# 17-0106)
        Description
        To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   NRG-LU002 Maintenance Systemic Therapy Versus Consolidative Stereotactic...
        Protocol No.
        HSC20170423XT
        Official Title
        NRG-LU002 Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial (CTMS# 17-0097)
        Description
        Phase II: To evaluate the impact of adding SBRT to maintenance systemic therapy versus maintenance systemic therapy alone on progression-free survival for patients with metastatic NSCLC with no evidence of progression and limited metastatic sites after first-line systemic therapy Phase III: To evaluate the impact of adding SBRT to maintenance systemic therapy versus maintenance systemic therapy alone on overall survival for patients with metastatic NSCLC with no evidence of progression and limited metastatic sites after first-line systemic therapy
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy...
        Protocol No.
        HSC20150302XT
        Official Title
        S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step) Lung-MAP Sub-Study (CTRC #14-0036)
        Description
        The overarching goal for this protocol is to establish a National Clinical Trials Network (NCTN) mechanism for genomically screening large but homogeneous cancer populations and subsequently assigning and accruing simultaneously to a multi-sub­ study Master Protocol. Biomarker-driven sub-studies in this protocol will compare new targeted therapy (TT) or targeted therapy combinations (TTC) to standard of care (SoC) therapy based on designated therapeutic biomarker-drug combinations, with the ultimate goal being approval of new targeted therapies in this setting. In addition, the protocol includes a non-match sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy (NMT) to SoC also with the goal of approval. We hypothesize that this Master Protocol mechanism will yield definable and measurable efficiencies in terms of improving genomic screening of cancer patients for clinical trial entry, and improved time lines for drug-biomarker testing allowing for inclusion of the maximum numbers of otherwise eligible patients in comparison with currently employed single screen-single trial approaches.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Lymphoid Leukemia

      •   AALL08B1, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
        Protocol No.
        HSC20110017X
        Official Title
        AALL08B1, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
        Description
        This research trial studies a risk-based classification system for patients with newly diagnosed acute lymphoblastic leukemia. Gathering health information about patients with acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best treatment.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk...
        Protocol No.
        HSC20110028X
        Official Title
        AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy) (CTRC HSC20110028X)
        Description
        This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk...
        Protocol No.
        HSC20120250X
        Official Title
        AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum (CTRC 12-0081)
        Description
        This randomized phase III trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed high-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC#...
        Protocol No.
        HSC20150314X
        Official Title
        AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL)and T- Lymphoblastic Lymphoma (T-LLy)A Groupwide Phase III Study (CTMS# 14-2028)
        Description
        Primary Aims: To compare EFS in patients with newly diagnosed T-ALL and T-LLy who are randomized to a modified ABFM backbone versus bortezomib plus the modified ABFM backbone. Secondary Aims: 1)To determine the safety and feasibility of modifying standard therapy for T-ALL and T-LLy based on the results of UKALL 2003, which includes a dexamethasone-based Induction, additional doses of pegaspargase (PEG-ASP) during Induction and Delayed Intensification (DI), and dexamethasone pulses during Maintenance therapy 2)To determine if prophylactic (presymptomatic) cranial radiation therapy (CRT) can be safely and effectively eliminated in the 85-90% of T-ALL patients classified as standard or intermediate risk. 3)To determine the proportion of EOC MRD 0.1% T-ALL patients who become MRD negative (undetectable by flow cytometry) after intensification of chemotherapy, using three high risk (HR) BFM blocks, and to compare EFS between the patients who become MRD negative after the three HR BFM blocks and continue on chemotherapy with those who continue to have detectable MRD and are eligible for other treatment strategies, including hematopoietic stem cell transplant (HSCT). Similarly, to compare the EFS between very high risk (Induction failure) T-LLy patients treated with HR BFM intensification blocks who have partial or complete response (PR or CR) with those who do not respond (NR). Correlative Aims: 1)To investigate the prognostic significance of Day 29 BM MRD in T-LLy patients. 2)To determine if protein expression patterns can predict bortezomib response and drug resistance in T-ALL 3)To analyze and target relevant signaling pathways in T-ALL blasts, focusing on Early T cell Precursor (ETP) ALL
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ACCL1333/CV185155A, Phase III Randomized, Open Label, Multi-center Study of...
        Protocol No.
        HSC20150889HU
        Official Title
        ACCL1333/CV185155A, Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-Asparaginase (CTMS# 15-2044)
        Description
        Primary Objectives: 1)To compare the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on the composite endpoint of adjudicated non-fatal deep vein thrombosis (DVT, including symptomatic and asymptomatic), pulmonary embolism (PE), and cerebral venous sinus thrombosis (CVST); and venous thromboembolism (VTE)-related-death during 25-28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning central venous access device (CVAD) and receiving PEG L-asparaginase during chemotherapy induction. 2)To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on adjudicated major bleeding events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. Secondary Objectives: 1) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single adjudicated endpoints of non-fatal DVT (including symptomatic and asymptomatic), PE, and CVST; and VTE-related-death during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 2) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on the composite endpoint of adjudicated major and clinically relevant non-major bleeding (CRNMB) events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed acute ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. Other Objectives: 1) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single adjudicated endpoints of all cause death; arterial thromboembolic events including paradoxical embolism and stroke and CVAD-related infection events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 2) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single adjudicated endpoints of CRNMB and minor bleeding events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 3) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single endpoints of number of catheter replacements needed during the study; events of CVAD dysfunction with improvement after thrombolytic therapy; and number of platelet transfusions during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 4) To assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy for ALL or lymphoma (T or B cell), using a population pharmacokinetic (PPK) approach. 5) To characterize the relationship between apixaban plasma concentration and anti-FXa activity in pedi
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   INCB 18424-269 (COG AALL1521), A Phase 2 Study of the JAK1/JAK2 Inhibitor...
        Protocol No.
        HSC20160625HU
        Official Title
        INCB 18424-269 (COG AALL1521), A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2 Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (CTMS# 16-0137)
        Description
        Primary Objectives: Part 1 - To evaluate initial safety and tolerability and to define the recommended Part 2 dose (RP2D) of ruxolitinib in combination with multi-agent chemotherapy in children and adolescents or young adults (AYA) with de novo high-risk (HR) Philadelphia chromosome like (Ph-like) cytokine receptor like factor 2 rearranged (CRLF2-R) and/or Janus kinase (JAK) pathway mutant B-cell acute lymphoblastic leukemia (B-ALL). Part 2 - To determine the efficacy of ruxolitinib in combination with chemotherapy for children and AYA with de novo HR Ph-like CRLF2-R and/or JAK pathway mutant B-ALL. Secondary Objective: - To characterize the safety and potential toxicity of ruxolitinib combined with chemotherapy throughout the course of treatment in children and AYA with de novo HR Ph-like CRLF2-R and/or JAK pathway mutant B-ALL. Exploratory Objectives: - To assess the pharmacokinetics (PK) of ruxolitinib in combination with chemotherapy in children and AYA with B-ALL. - To assess rates of minimal residual disease (MRD) at end-Consolidation in end-Induction MRD+ subjects who are treated with ruxolitinib and chemotherapy. - To measure pharmacodynamic (PD) signaling inhibition and biomarkers of ruxolitinib activity, for correlation with ruxolitinib PK and with efficacy measures. - To evaluate the overall survival (OS) of all subjects receiving ruxolitinib in combination with chemotherapy.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Multiple Myeloma

      •   An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab,...
        Protocol No.
        HSC20160389HU
        Official Title
        An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma (CheckMate 602: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 602) (CTMS# 16-0039)
        Description
        Primary Objectives: The co-primary objectives are to compare the following between N-Pd and Pd arms: The objective response rate (ORR) by IRC The progression free survival (PFS) by IRC Secondary Objectives To assess the time to objective response (TTR) within N-Pd and Pd arms To assess the duration of objective response (DOR) within N-Pd and Pd arms To assess ORR and PFS by Investigator within N-Pd and Pd arms Exploratory Objectives To estimate overall survival of each of the 3 treatment groups To evaluate efficacy of NE-Pd in subjects with relapsed and/or refractory multiple Myeloma within NE-Pd arm through the assessment of ORR and PFS To evaluate efficacy of NE-Pd in subjects cross-over from the control arm (Pd) to the exploratory arm (NE-Pd) through the assessment of ORR and PFS To assess safety and tolerability To characterize the pharmacokinetics of nivolumab and elotuzumab when administered in combination with elotuzumab, pomalidomide and dexamethasone To characterize the immunogenicity of nivolumab and elotuzumab when administered in combination with elotuzumab, pomalidomide and dexamethasone To assess patient-reported outcomes in disease-related symptoms using MDASI-MM, EORTC QLQ-C30 and EQ-5D
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Bortezomib or Carfilzomib with Lenalidomide & Dexamethasone in patients with...
        Protocol No.
        HSC20150407XT
        Official Title
        E1A11, Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) (CTMS 15-2043)
        Description
        Primary Objective To compare the overall survival between two strategies of lenalidomide maintenance following induction with a proteasome inhibitor IMiD combination: limited duration of maintenance (24 months) versus indefinite maintenance therapy until disease progression. Secondary Objectives To compare the progression-free survival between two strategies of lenalidomide maintenance following induction with a proteasome inhibitor IMiD combination: limited duration of maintenance (24 months) or indefinite maintenance therapy until disease progression. To compare the progression-free survival between VRd and CRd induction followed by lenalidomide maintenance in patients with newly diagnosed symptomatic multiple myeloma. To compare induction rates of response between VRd and CRd arms. To evaluate the time to progression, duration of response and overall survival between VRd and CRd induction therapy. To compare induction rates of toxicity between VRd and CRd arms. To evaluate toxicity during lenalidomide maintenance. Quality of Life Objectives To compare the short and long-term health-related quality of life impact between two strategies of lenalidomide maintenance following induction with a proteasome inhibitor IMiD combination: limited duration of maintenance (24 months) versus indefinite maintenance therapy until disease progression. To compare the impact on health-related quality of life between VRd and CRd induction therapy. To evaluate the association between early induction response and change in health-related quality of life. To describe changes in health-related quality of life during the induction, active maintenance and observation phases. To evaluate correlation between treatment adherence during maintenance and health-related quality of life. Correlative Laboratory Study Objectives To compare induction minimal residual disease negativity rates between VRd and CRd arms. To compare minimal residual disease negativity rates between two strategies of lenalidomide maintenance following induction with a proteasome inhibitor IMiD combination: limited duration of maintenance (24 months) versus indefinite maintenance therapy until disease progression. To describe changes in minimal residual disease during the induction and active maintenance phases and explore association with response.
        Contact
        210-450-5798
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with...
        Protocol No.
        HSC20150751HU
        Official Title
        MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) (CTMS# 15-2082)
        Description
        Primary Objective To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. Secondary Objectives To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas. To evaluate time until death or disease progression. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, RNA and protein-based assessment platforms.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Myeloid and Monocytic Leukemia

      •   A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety...
        Protocol No.
        HSC20170513XT
        Official Title
        A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and Without Red Blood Cell-Transfusion Dependence (CTMS# 17-0078)
        Description
        The primary objective of this study is: to evaluate the efficacy and safety of luspatercept for the treatment of anemia in subjects with MPN-associated myelofibrosis with and without RBC-transfusion dependence.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AAML1531 - Risk-stratified Therapy for Acute Myeloid Leukemia in Down...
        Protocol No.
        HSC20170204XT
        Official Title
        AAML1531 - Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome. A COG Groupwide Phase 3 Study (CTMS# 17-0058)
        Description
        1.1 Primary Aims 1.1.1 To determine the 2-year event-free-survival (EFS) for children with standard risk DS AML (MRD-negative after one cycle of induction therapy) after elimination of HD Ara-C from the treatment regimen. 1.1.2 To determine the 2-year EFS for children with high risk DS AML (MRD-positive after one cycle of induction therapy) after intensification of treatment equivalent to that used for high risk AML in children without DS. 1.2 Exploratory Aims 1.2.1 To determine the extent to which elimination of HD Ara-C from the treatment of standard risk DS AML decreases adverse events and resource utilization. Specifically, to determine if elimination of HD Ara-C from treatment of standard risk DS AML results in: 1.2.1.1 A significant decrease in the number of days per patient spent on protocol therapy compared to predecessor study AAML0431. 1.2.1.2 A significant decrease in the average number of days of hospitalization per patient compared to predecessor studies AAML0431 and A2971. 1.2.1.3 A significant decrease in the number (per patient) and rate (per duration of treatment) of sterile site infections compared to the predecessor study AAML0431. 1.2.1.4 A significant decrease of resource utilization by AML treatment compared to the predecessor study AAML0431. 1.2.2 To compare the feasibility and analytical characteristics of flow cytometry, PCR and targeted error-corrected sequencing of GATA1 mutations as methods to detect MRD in DS AML. 1.2.3 To establish a DS AML cell bank of viably frozen bone marrow samples collected at the end of induction and corresponding non-tumor DNA samples collected at end of Induction 1.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Non-Hodgkin Lymphoma

      •   A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or...
        Protocol No.
        HSC20160299XT
        Official Title
        A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117 (CTMS 16-0059)
        Description
        1.1 Primary Aims 1.1.1 Tolerability - To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (ALCL99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99). 1.1.2 Event Free Survival -To estimate the Event Free Survival (EFS) of Arm BV and Arm CZ and contrast these to historical control data. 1.2 Secondary Aim 1.2.1 MDD/MRD - To determine the prognostic significance of minimal disseminated disease (MDD) at diagnosis and minimal residual disease (MRD) as measured by RT- polymerase chain reaction (PCR) in peripheral blood.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase Ib clinical trial of roflumilast added to standard chemoimmunotherapy...
        Protocol No.
        HSC20180073HU
        Official Title
        Phase Ib clinical trial of roflumilast added to standard chemoimmunotherapy for high-risk diffuse large B-cell lymphoma (CTMS# 17-0087)
        Description
        To determine the safety and tolerability of oral roflumilast at a dose of 500 µg daily given concurrently with R-CHOP to patients with newly diagnosed DLBCL at moderate or high risk for poor outcomes, defined as an NCCN-IPI score of 2 or greater.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Other Endocrine System

      •   ANBL1232 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy...
        Protocol No.
        HSC20150496X
        Official Title
        ANBL1232 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma: A Groupwide Historically Controlled Phase III Study (CTRC# 15-0007)
        Description
        ANBL1232
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Genetic Analysis of Pheochromocytomas and Paragangliomas (CTRC# 15-0004)
        Protocol No.
        HSC20060069H
        Official Title
        Genetic Analysis of Pheochromocytomas and Paragangliomas (CTRC# 15-0004)
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Other Hematopoietic

      •   An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in...
        Protocol No.
        HSC20170540XT
        Official Title
        An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib (CTMS# 17-0102)
        Description
        The primary objective is to determine a recommended dosage of pacritinib for further clinical studies.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Ovary

      •   Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low...
        Protocol No.
        HSC20170396HU
        Official Title
        Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women (CTMS# 17-0014)
        Description
        To evaluate the longitudinal CA-125 algorithm for the early detection of ovarian cancer in a low risk cohort of women.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Prostate

      •   A Two-Part Prospective Study to Measure the Impact of Adding Genomic Testing...
        Protocol No.
        HSC20160493HU
        Official Title
        A Two-Part Prospective Study to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients with Long Term Follow-up Post-Treatment to Measure the Prediction of Progression/Recurrence in Men Treated in the Veterans Administration Medical Center (VAMC) P-PROVE - Prospective Prolaris® Value and Efficacy (CTMS 16-0132)
        Description
        The objectives of the study include: ¿ To estimate the impact of a biopsy based genomic risk assessment tool (Prolaris®) on the magnitude of change between the PRE-Prolaris® test selection of treatment option for clinically localized prostate cancer and the ACTUAL implemented treatment administered following the genomic test results.  To estimate the impact of a biopsy based genomic risk assessment tool (Prolaris®) on the magnitude of change between the PRE-Prolaris® test selection of treatment option for early-stage prostate cancer and the POSTProlaris ® test treatment plan following consultation with the patient.  To estimate the impact of a biopsy based genomic risk assessment tool (Prolaris®) on the magnitude of change between physician''s initial likelihood of recommending non-interventional therapy for early-stage prostate cancer and the likelihood following the genomic test results
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Interventional Study to Reduce Folate Levels in Men on Active...
        Protocol No.
        HSC20160340HU
        Official Title
        An Interventional Study to Reduce Folate Levels in Men on Active Surveillance for Prostate Cancer (CTMS# 16-0070)
        Description
        Ascertain the impact of a low folate (folic acid) enriched diet- a reverse dietary intervention- on prostate cancer prevention and progression.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Biomarkers and clinical parameters associated with Gleason score upgrading...
        Protocol No.
        HSC20140367H
        Official Title
        Biomarkers and clinical parameters associated with Gleason score upgrading (CTRC# 14-0031)
        Description
        This study involves the collection of blood samples by finger stick, heel stick, ear stick, or venipuncture from unhealthy adults, pregnant adults or children.  Considering the person’s age, weight, and health, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected the blood samples intended for this study are minimal risk.
        Contact
        210-567-0178
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Canary Prostate Active Surveillance Study (PASS) (CTRC# 20080303H)
        Protocol No.
        HSC20080303H
        Official Title
        Canary Prostate Active Surveillance Study (PASS) (CTRC# 20080303H)
        Description
        All care participants receive is Standard of Care for Active Surveillance.  Research procedures include blood draw every 6 months for serum and plasma, urine collections, prostate tissue collection, Food & Supplement Use Questionnaire and the Health-Related Quality of Life Questionnaire.  Purpose of the PASS is to understand how prostate cancer behaves and to find unique biomarkers (substances in blood, urine or tissue which can indicate the presence of cancer) associated with prostate cancer
        Contact
        210-450-0705
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Clinical Evaluation of the ExoDx Prostate (IntelliScore) in men presenting...
        Protocol No.
        HSC20170067HU
        Official Title
        Clinical Evaluation of the ExoDx Prostate (IntelliScore) in men presenting for initial biopsy: impact on decision-making and health economics (CTMS 16-0040)
        Description
        1.1. Primary Objective 1.1.1. Evaluate impact of the ExoIntelliScore Prostate on the decision to perform an initial prostate biopsy for men presenting with an elevated PSA (2-10 ng/mL). 1.2. Secondary and Exploratory Objectives 1.2.1. Assess physician satisfaction with the ExoIntelliScore Prostate report including test result presentation, graphics and interpretation. 1.2.2. Assess patient satisfaction for ease of understanding test results and role on decision process to have a biopsy. 1.2.3. Determine the medical economic impact of the ExoIntelliScore Prostate in the prostate biopsy decision process. 1.2.4. Correlation of the ExoIntelliScore Prostate score with the actual biopsy result. 1.2.5. The goal of this study is to evaluate how the urologist will utilize the ExoIntelliScore Prostate score in the decision process to perform an initial prostate needle biopsy for men presenting for an equivocal PSA.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Cognitive impairment associated with androgen deprivation therapy (ADT)...
        Protocol No.
        HSC20160519HU
        Official Title
        Cognitive impairment associated with androgen deprivation therapy (ADT) (CTMS# 16-0103)
        Description
        To assess the effects of androgen-deprivation therapy on cognition among aging men with prostate cancer
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Dynamic Multi-Cohort Prediction Modeling of Prostate Biopsy Outcome (CTRC#...
        Protocol No.
        HSC20150050H
        Official Title
        Dynamic Multi-Cohort Prediction Modeling of Prostate Biopsy Outcome (CTRC# 14-0053)
        Description
        Dynamic Multi-Cohort Prediction Modeling of Prostate Biopsy Outcome
        Contact
        210-450-0754
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Establishing Community-Based Normal Distributions of Selected Urinary Biomarkers
        Protocol No.
        HSC20110312H
        Official Title
        Establishing Community-Based Normal Distributions of Selected Urinary Biomarkers
        Description
        This research study has been ongoing for 10 years and originally funded by the American Cancer Society.  For the past 3 years it has been funded by the National Cancer institute but with a different focus.  The three goals of this study are: To improve the accuracy of screening tests for the diagnosis of prostate cancer. Identify biomarkers that will predict how aggressive prostate cancer will be.  The tests currently in use for screening for prostate cancer are the PSA blood test and digital rectal examination (DRE) of the prostate.  When either or both of these tests are positive, a tissue biopsy of the prostate is recommended. The third goal is to provide accurate information about how rapidly prostate cancers will become worse.  To accomplish this we will study tissue and blood to identify proteins and genes that are present at high or low levels in prostate cancers that progress slowly versus those that progress more rapidly.
        Contact
        210-567-0178
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Hormonal Therapy plus Radiation Therapy as Treatment for Prostate Cancer
        Protocol No.
        HSC20130062H
        Official Title
        RTOG 0924 Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial (CTRC# 12-0089)
        Description
        The purpose of this study is determine which type of anti-hormonal therapy and radiation therapy will result in an improvement in survival in patients with “unfavorable” intermediate risk or “favorable” high risk prostate cancer.  The risk is the possibility or chances of the prostate cancer coming back after being treated. The primary objective is to see which treatment improves the duration of survival. The study will enroll 2,580 participants from many cancer centers in the US. In addition to other conditions for enrollment, men who were diagnosed with prostate cancer within the past 180 days and have no evidence of lymph node involvement by CT scan or MRI within the past 90 days may be enrolled. Men are not eligible for this study if the prostate or testes have been surgically removed. Men who have already been treated with brachytherapy or radiation to the pelvis or hormonal therapy are not enrolled. Patients with a history of other cancers may not be eligible.
        Contact
        210-450-5924
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Impact of a home-based exercise program on prognostic biomarkers in men with...
        Protocol No.
        HSC20160604HU
        Official Title
        Impact of a home-based exercise program on prognostic biomarkers in men with prostate cancer (CTMS 15-0008)
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Impact of Yoga as Complementary Therapy on Quality of Live, Pro-Inflammatory...
        Protocol No.
        HSC20150406H
        Official Title
        Impact of Yoga as Complementary Therapy on Quality of Live, Pro-Inflammatory and Cellular Immune Biomarkers in Patients Undergoing Radical Prostatectomy: A Pilot Randomized Controlled Trial (CTRC# 15-0003)
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Improving the Detection of Prostate Cancer in Men with Low Serum PSA (CTMS...
        Protocol No.
        HSC20160310HU
        Official Title
        Improving the Detection of Prostate Cancer in Men with Low Serum PSA (CTMS 16-0055)
        Description
        Utilize biomarkers and imaging to identify men who have prostate cancer but low PSA levels.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Prostate MRI as a Screening Tool to Detect Prostate Cancer (Novel Prostate...
        Protocol No.
        HSC20150160H
        Official Title
        Prostate MRI as a Screening Tool to Detect Prostate Cancer (Novel Prostate MRI Technique as a Prostate Cancer Biomarker) (CTRC# 15-0001)
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Prostate Wash Epithelial Cell Repository (PWER) (CTRC#12-0070)
        Protocol No.
        HSC20120262H
        Official Title
        Prostate Wash Epithelial Cell Repository (PWER) (CTRC#12-0070)
        Description
        This tissue bank will store epithelial cell samples from prostate biopsies and measure Prostate Specific Antigen (PSA) and Prostate Specific Membrane Antigen (PSMA) in the urine specimens for future scientific research studies.  The stored specimens will be used for research investigating the causes of prostate diseases, the methods for improving diagnosis, and highly aggressive forms from less aggressive forms of prostate cancers.
        Contact
        210-450-0754
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) (CTRC...
        Protocol No.
        HSC20000030H
        Official Title
        San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) (CTRC HSC20000030H)
        Description
        The San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR), is a long-term research study of a large group of men that will help researchers improve the detection of prostate cancer.  The program provides annual PSA (Prostate Specific Antigen) screening at no cost.  Subjects participating in this study will be asked to attend one visit per year for PSA screening and complete annual follow-up phone interviews. Written PSA results will be provided to you, and if you request, to your provider
        Contact
        210-567-0178
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue,...
        Protocol No.
        HSC20130013H
        Official Title
        Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue, Quality Of Life and Physical Function in Prostate Cancer Survivors (CTRC 12-0085)
        Description
        This study is designed as a cross-sectional, exploratory pilot study to examine the onset and progression of cancer-related fatigue in prostate cancer patients. The goal of this project is to report the effect of fatigue on quality of life and pilot a novel salivary biomarker to measure fatigue. One hundred men, diagnosed with prostate cancer and 200 men without prostate cancer will be recruited to participate in this study. Detailed medical and medication history will be reviewed to determine if subjects are eligible to participate in this study. All eligible participants will be recruited to participate in this study. All activities will be done during the patients regularly scheduled visit with their oncologist at the CTRC. Each subject will sign an informed consent form indicating their willingness to participate after which they will complete a battery of survey instruments and provide a 4 mL saliva sample. Saliva will be used to assess concentrations of a fatigue biomarkers in this study and banked for future research studies. The total length of time for study participation for each subject should be less than 1 hour.
        Contact
        210-567-0362
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Tissue Bank and Data Base for Urologic Diseases (CTRC HSC20050234H)
        Protocol No.
        HSC20050234H
        Official Title
        Tissue Bank and Data Base for Urologic Diseases (CTRC HSC20050234H)
        Description
        The purpose of this project is to establish a high-quality repository of male and female genitourinary tissue specimens with an associated database of relevant clinical, follow-up and outcome data.  Development and maintenance of a high-quality repository is essential to the conduct of translational research for genitourinary cancer. When possible, specimens will be accrued by freezing fresh excess tissue removed at surgery or biopsy. No extra tissue will be removed during surgery expressly for the repository. Specimens will also be obtained from archival paraffin-embedded tissue. Clinical data will be obtained from tumor registry files, from subjects, or review of medical records.
        Contact
        210-567-0178
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Soft Tissue

      •   A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
        Protocol No.
        HSC19990345X
        Official Title
        A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
        Description
        The purpose of this study is to collect and store tumor tissue, blood, and bone marrow samples from patients with soft tissue sarcoma that will be tested in the laboratory. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients to test in the laboratory may help the study of cancer.
        Contact
        210-562-9149
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide...
        Protocol No.
        HSC20160538XT
        Official Title
        A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) (CTMS 16-0116)
        Description
        Primary Aims: 1.1 To compare the event-free survival (EFS) of patients with IR RMS treated with surgery, radiotherapy, and VAC alternating with VI (VAC/VI) to that of patients treated with surgery, radiotherapy and VAC/VI plus temsirolimus (TORI). Secondary Aims: 1.2 To compare the overall survival (OS) of patients with IR RMS treated with surgery, radiotherapy, and VAC alternating with VI to that of patients treated with surgery, radiotherapy and VAC/VI plus TORI. Exploratory Aims: 1.3.1 To compare the outcome of patients based on their FOXO1 fusion gene partner, by evaluation PAX3 vs. PAX7 in all patients found to be FOXO1 fusion positive. 1.3.2 To compare the outcome of patients based on their [F18]-fluorodeoxy-D-glucose-positron emission tomography (FDG-PET) response at Week 9 (positive or negative), as assessed by Deauville Criteria (5-point).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   ARST1321 - Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue...
        Protocol No.
        HSC20150224X
        Official Title
        ARST1321 - Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) (CTMS# 14-0043)
        Description
        ARST1321
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Stomach

    •   Unknown sites

      •   Tanning Attitudes and Behaviors in Adolescent and Young Adults (CTMS# 18-0008)
        Protocol No.
        HSC20180055HU
        Official Title
        Tanning Attitudes and Behaviors in Adolescent and Young Adults (CTMS# 18-0008)
        Description
        To understand tanning attitudes and behaviors in an adolescent and young adult population. To inquire about sunscreen use and discover effective means of communication to explain the risk of sun exposure and importance of sunscreen use to this at risk population.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Urinary Bladder

      •   A Phase III, Open Label Study to Evaluate the Safety and Efficacy of...
        Protocol No.
        HSC20160351HU
        Official Title
        A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd- IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC) (CTMS 16-0042)
        Description
        To evaluate the incidence of Event-Free Survival at 12 months, where Event-Free Survival is defined as High-Grade-Recurrence Free Survival
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Randomized study of rapamycin combined with intravesical BCG in patients...
        Protocol No.
        HSC20160162HU
        Official Title
        A Randomized study of rapamycin combined with intravesical BCG in patients with non-muscle invasive bladder cancer (CTMS 16-0011)
        Description
        1.1 The primary objectives of the study are to determine: a. The effect of Sirolimus on BCG-specific immunity during treatment of non-muscle invasive bladder cancer with maintenance BCG 1.2 Secondary objectives of the study are to determine: a. The compare the effects of very low-dose versus low-dose Sirolimus on BCG-specific immunity during treatment of non-muscle invasive bladder cancer with maintenance BCG
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Evaluating responses to intravesical BCG administration to patients with...
        Protocol No.
        HSC20140002H
        Official Title
        Evaluating responses to intravesical BCG administration to patients with invasive bladder cancer: Defining mechanisms of mTOR inhibition to boost immunotherapy in bladder cancer and Improving immunotherapy in bladder cancer by targeting immune dysfunction (CTRC# 13-0051)
        Description
        Patients with muscle invasive (≥T1) bladder cancer will be given 3-6 treatments (based on treatment response) intravesically TICE® BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. After completion of BCG treatments the patient will undergo a cystectomy. A portion of bladder tumor tissue and lymph nodes will be collected for research purposes during the cystectomy.
        Contact
        210-450-0507
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Multi-Institutional Study to Evaluate DNA Methylation Markers for Detection...
        Protocol No.
        HSC20160419HU
        Official Title
        Multi-Institutional Study to Evaluate DNA Methylation Markers for Detection of Primary Bladder Cancers in Urine Samples From a Cohort of Patients With Hematuria (CTMS 16-0094)
        Description
        The primary objective of this study is to evaluate the performance of the methylation marker panel for the detection of bladder cancer in patients with gross or microscopic hematuria. The secondary objective is to evaluate the predictive accuracy of a risk model including clinical factors such as age, gender, smoking history, and presence of gross versus microscopic hematuria compared to a model incorporating the same risk factors along with the methylation marker panel.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Repository for Bladder and Genitourinary Cancer (CTRC# 12-0056)
        Protocol No.
        HSC20120159H
        Official Title
        Repository for Bladder and Genitourinary Cancer (CTRC# 12-0056)
        Description
        The primary objective of this repository is to collect and store specimens from patients with suspicion of or diagnosed with bladder cancer.  These specimens will be used to determine the local and systemic immune profiles of patients with bladder cancer.
        Contact
        210-450-0507
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain...
        Protocol No.
        HSC20170087HU
        Official Title
        S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer (CTMS# 16-0138)
        Description
        Primary Objectives To compare whether time to high-grade recurrence (TTHGR) for patients with BCG-naive, non-muscle invasive bladder cancer (NMIBC) receiving Tokyo-172 BCG strain (Arm 2) is non-inferior to patients receiving BCG LIVE (TICE® BCG) strain (Arm 1). To test whether TTHGR for patients with BCG-naive, NMIBC receiving intradermal Tokyo-172 BCG vaccination followed by intravesical Tokyo-172 BCG instillation (Arm 3) is superior to patients receiving intravesical Tokyo-172 BCG instillation without prior intradermal BCG vaccination (Arm 2). Secondary Objectives To compare time to recurrence (TTR) with any-grade (AG) bladder cancer between: 1. Patients receiving Tokyo-172 versus BCG LIVE (TICE® BCG) strain, 2. Patients receiving intradermal + intravesical versus intravesical only Tokyo-172 BCG. To compare progression-free survival (PFS) between: 1. Patients receiving Tokyo-172 versus BCG LIVE (TICE® BCG) strain, 2. Patients receiving intradermal + intravesical versus intravesical only Tokyo-172 BCG. c. To compare 6-month complete response in patients with Carcinoma in situ (CIS) present at baseline with or without Ta or T1 cancer receiving: 1. Tokyo-172 versus BCG LIVE (TICE® BCG) strain, 2. Intradermal + intravesical versus intravesical only Tokyo-172 BCG.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1605, Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle...
        Protocol No.
        HSC20180230XT
        Official Title
        S1605, Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (CTMS# 18-0014)
        Description
        To estimate complete response at 25 weeks after registration for those with a CIS component and to evaluate event-free survival at 18 months in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (Ta/T1/CIS) treated with atezolizumab.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Surveillance for low and low-intermediate-risk non-muscle invasive bladder...
        Protocol No.
        HSC20130177H
        Official Title
        Surveillance for low and low-intermediate-risk non-muscle invasive bladder cancer: A Pilot Study (CTRC#12-0108)
        Description
        This is a two-arm, randomized-controlled pilot study with 2 year duration. The "intervention" refers to surveillance based on the EAU guidelines and the "control" refers to surveillance based on the AUA guidelines. Research methods: Participants who presents with non-muscle invasive bladder cancer and meets the inclusion/exclusion criteria will be given an option to participate in the study. Participants will be enrolled at the Urology Clinics at the University of Texas Health Science Center San Antonio (UTHSCSA) Medical Arts and Research Center (MARC) and South Texas Veterans Health Care System (STVHCS). Non-local site include the University of Texas Southwestern Medical Center (UTSW). The research procedures consist of urine collection, cystoscopy, and patient satisfaction and cost questionnaires. The evaluation will be done by the tumor recurrence and progression of the disease. At various time points throughout the study, urine may be obtained from the patient and banked in the Genitourinary (GU) Tissue Bank. Subjects asked to provide a urine sample(s) will be asked to sign a separate informed consent. The urine is de-identified in the lab per the Health Insurance Portability and Accountability Act (HIPAA) protocol GU Tissue Bank Institutional Review Board (IRB) # 20050234H). Patients will undergo cystoscopy in clinic (standard of care). In the intervention arm, patient surveillance cystoscopy will be performed at 3, 12 months and again at 24 months following the diagnosis of bladder cancer. Patients randomized to the control arm, will undergo surveillance cystoscopy every 3 months for 2 years following the diagnosis of bladder cancer. Because use of cytology is variable among the participating urologist, the utilization of cytology will be at the treating urologist''s discretion as per usual standard care. Study duration will be 2 years from most recent biopsy. Patients will be placed on the surveillance schedule based on the length of time from their last tumor.
        Contact
        210-450-0507
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

  •   Children's Health

    •   A study of a new medicine for the treatment of...
      Protocol No.
      HSC20170700H
      Official Title
      A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Safety, and Efficacy Study of SHP465 in Children Aged 6-12 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)
      Description
      Children aged 6 to 12 years of age will have an evaluation to determine if they have ADHD. They then will be selected at random (like a flip of a coin) to either receive a medicine for ADHD (SHP465) or a placebo (an empty pill) for four weeks.
      Contact
      210-450-8405
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   A study of a new medicine for the treatment of...
      Protocol No.
      HSC20170701H
      Official Title
      A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactivity Disorder
      Description
      Children aged 4 to 12 years of age will have an evaluation to determine if they have ADHD. This study will be using an investigational drug (SHP465) for the treatment of ADHD. Participation in this study will last about 52 weeks.
      Contact
      210-450-8405
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   A study of carfilzomib in combination with cyclophosphamide and etoposide...
      Protocol No.
      HSC20160206H
      Official Title
      Phase I study of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
      Description
      To evaluate the highest dose of carfilzomib that can be given safely together with cyclophosphamide and etoposide for children with solid tumor or leukemia that is not yielding to standard treatment and or is worsening.
      Contact
      210-562-9025
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND...
      Protocol No.
      HSC20150549H
      Official Title
      AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS (CTRC# 15-0006)
      Description
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genetic and Environmental Influences on Growth, Motor, Cognitive, Behavioral...
      Protocol No.
      HSC20090012H
      Official Title
      Genetic and Environmental Influences on Growth, Motor, Cognitive, Behavioral and Language Development of Premature Infants
      Description
      A research study to understand how genes and the environment affect premature birth and infant development.
      Contact
      210-567-5225
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genomics of immune mediated diseases
      Protocol No.
      HSC20160018H
      Official Title
      Genomics of Immune Mediated Diseases
      Description
      New diseases of the immune system can be discovered by studying the genetic makeup of patients with a strong family history. In addition to providing a diagnosis, genetic studies can suggest better treatments in some cases. We are looking for children with immune mediated symptoms, including immune deficiency, inflammatory symptoms such as fever, and episodes of swelling, with at least one close relative (parent or sibling) who has the same symptom(s) and another who is not affected. Blood samples will be taken and analyzed for genetic differences.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   GO29665, A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE...
      Protocol No.
      HSC20160080H
      Official Title
      GO29665, A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF COBIMETINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS (CTRC# 15-0005)
      Description
      CTRC# 15-0005
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Health4Kids Intervention Trial for Hispanic Families
      Protocol No.
      HSC20130465H
      Official Title
      Health4Kids (H4K) Intervention Trial for Hispanic Families
      Description
      Health4Kids is an obesity management study that uses family counseling, text messages and newsletters to encourage healthy eating and physical activity. This study enrolls 6-11 year-old, obese/overweight Latino children (and a parent) who are existing patients at University Health System pediatric clinics in San Antonio.
      Contact
      210-562-6514
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Improvements in Brain Function during Psychotherapy For Teens with Symptoms...
      Protocol No.
      HSC20160637H
      Official Title
      Improvements in Brain Function during Psychotherapy For Teens with Posttraumatic Stress
      Description
      The purpose of the study is to analyze how brain functioning improves when symptoms of posttraumatic stress improve during psychotherapy. Teens who have experienced trauma and are bothered by symptoms of stress will be provided with the ‘gold-standard’ psychotherapy for trauma, at no-cost. They will have brain scans using Magnetic Resonance Imaging (MRI) before, during, and after the treatment: a total of 4 brain scans over the 20-week treatment. MRI is safe and does not use radiation or injections.
      Contact
      210-567-8162
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with...
      Protocol No.
      HSC20170289H
      Official Title
      A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY AND OPEN-LABEL EXTENSION
      Description
      The main goals of this study are to obtain additional information on whether the actions of ataluren can slow disease progression
      Contact
      210-567-8222
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   POE16-01, A study of neratinib in children and adolescent and young adults...
      Protocol No.
      HSC20170390H
      Official Title
      POE16-01, A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Hematologic Malignancies
      Description
      To evaluate the highest dose of neratinib that can be given safely for children with solid tumor or leukemia that is not yielding to standard treatment and or is worsening.
      Contact
      210-743-2332
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Chromosome 18 Clinical Research Center.
      Protocol No.
      HSC20000318H
      Official Title
      The Chromosome 18 Clinical Research Center.
      Description
      To learn as much as possible about the medical and educational effects of a chromosome 18 deletion or duplication, and to learn about the genes that are duplicated or deleted.
      Contact
      210-567-5321
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Understanding the genetics of bipolar I disorder in adolescents
      Protocol No.
      HSC20150334H
      Official Title
      Application of induced pluripotent stem cells for the study of bipolar I disorder
      Description
      The purpose of this research is to develop a cell-based system to study adolescent bipolar I disorder to better understand genetic and epigenetic mechanisms associated with risk and develop new methods for treatment. We will perform MRI, neurocognitive and neuropsychiatric testing and draw blood.
      Contact
      210-258-9766
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Diabetes

    •   Can the following Diabetes Medications: GLP-1 Receptor Agonist, Exenatide,...
      Protocol No.
      HSC20170582H
      Official Title
      SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTION Significance : Protocol- 4 Can the GLP-1 Receptor Agonist, Exenatide, Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
      Description
      We are working on a research study that examines diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration. We will examine the difference in Endogenous Glucose Production between the drug-treatment (Dapagliflozin) and Placebo-treatment groups.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Colesevelam Oral Suspension as Monotherapy or Add on to Metformin Therapy in...
      Protocol No.
      HSC20110050H
      Official Title
      Colesevelam Oral Suspension as Monotherapy or Add on to Metformin Therapy in Pediatric Subjects with Type 2 Diabetes Mellitus Protocol WEL-A-U307
      Description
      The primary objective of the study is to demonstrate the effects of covesevelam HCI oral suspension as monotherapy or as an addon therapy to metformin on change in HbA1c from baseline over the first 6-month treatment period in pediatric subjects with type 2 diabetes mellitus.
      Contact
      210-704-4443
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Durability of Early Combination Therapy vs Conventional Therapy in New Onset...
      Protocol No.
      HSC20080456H
      Official Title
      Durability of Early Combination Therapy vs Conventional Therapy in New Onset Diabetes
      Description
      This research study is exploring the way we currently prescribe medications to treat type 2 DM. Step-therapy (Conventional Therapy) with metformin, then a sulfonylurea, then basal insulin, as needed to optimize glycemic control is being compared to therapy with three medications from enrollment (Early Combination). These medications include metformin, pioglitazone, and exenatide.
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of GLP-1 Receptor Agonist, Exenatide on Glucosuria Induced Elevation...
      Protocol No.
      HSC20160597H
      Official Title
      Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
      Description
      Examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration. Hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects.
      Contact
      567-6710
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   EFFECT OF DIABETIC MEDICINES ( FARXIGA AND METFORMIN) ON RENAL FUNCTION AND...
      Protocol No.
      HSC20160262H
      Official Title
      EFFECT OF FARXIGA ON RENAL FUNCTION AND SIZE IN TYPE 2 DIABETIC PATIENTS WITH HYPERFILTRATION
      Description
      We propose to treat newly diagnosed T2DM patients with Farxiga or metformin for 4 months. Inclusion Criteria: (i) age = 30-70 years; (ii) BMI = 20-45 kg/m2; (iii) A1c = 7.5% to 12%; (iv) male or female; (v) willingness to participate in the 16 week study protocol
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of the Diabetes Medication - Dapagiflozin on glucose use by the liver
      Protocol No.
      HSC20170214H
      Official Title
      Effect of Dapagiflozin on hepatic glucose metabolism: role of autonomic nervous system
      Description
      Dapagliflozin is a novel unique drug recently approved by the FDA for the treatment of type 2 diabetes. In previous studies, we found that in addition to lowering glucose sugar levels in the blood, dapagliflozin increases glucose sugar production by the liver and increases the rate of fat oxidationburning fat in the body. These actions of the drug decrease its effectivnessefficacy in lowering the blood sugar and increase the risk of complications. The aim of of the presentthis study is to understand the mechanism way by whichthat dapagliflozin causes the liver to increase sugar production and fat burning so that these actions, this allows us we can tothen develop methods to prevent them. You are being asked to be a participant in this study because you have type 2 diabetes and your blood sugar is not too high that requires treatment with medications. Or you do not have diabetes and the results of your tests will be used to compare to those with diabetes.
      Contact
      210-567-6710
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Illness representations in elders living in the United States with Multiple...
      Protocol No.
      HSC20160103H
      Official Title
      Illness Representations in Elders Living in the United States with Multiple Chronic Conditions: A Mixed Methods Study
      Description
      Multiple Chronic Conditions (MCC) are two or more long-lasting conditions that may be controlled but not cured. Illness representation (IL) is how a person feels about and manages their chronic condition. Coping procedures are actions taken to manage a condition and appraisal represents the evaluation of how one manages their condition. Understanding IL,coping procedures and appraisals may help to improve management of multiple chronic conditions.
      Contact
      210-291-7358
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Impact of the microbiome on diabetes health disparities
      Protocol No.
      HSC20170385H
      Official Title
      The Microbiome as a Potential Mediator of Diabetes Health Disparities
      Description
      This study will compare the gut microbiome of Mexican Americans with and without diabetes and determine the impact of other health disparity contributing factors on the microbiome composition. Links between the gut microbiome and health could provide novel prevention and intervention strategies for health disparities.
      Contact
      210-567-8345
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Metabolism Study: Microbiome-Induced Insulin Resistance (Aim 2)
      Protocol No.
      HSC20130458H
      Official Title
      Mechanism of Microbiome-Induced Insulin Resistance in Humans (Aim 2)
      Description
      Aim 2: This outpatient study will evaluate how a probiotic (a type of good bacteria) or study medication (sevelamer)/placebo will affect the metabolism. Recent research suggests that people who are overweight or who have Type 2 diabetes have an elevation in the level of a substance called "endotoxin” in the blood. This study will examine if lowering the level of endotoxins will improve the way the body metabolizes (burns) sugars. We will enroll 3 populations: healthy people without diabetes who are lean and have no family history of diabetes; obese (BMI 30-37) non-diabetics without family history; and obese with Type 2 diabetes not taking insulin or metformin. Volunteers will be non-smokers between the ages of 18 and 65, sedentary lifestyle, stable body weight for >3 months, without recent heart attack or other clinical diagnosis not on stable treatment regimen.
      Contact
      210-450-0020
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Paradoxical Stimulation of Hepatic Glucose Production with Dapagliflozin (P2)
      Protocol No.
      HSC20160586H
      Official Title
      Paradoxical Stimulation of Hepatic Glucose Production with Dapagliflozin (P2)
      Description
      The present study will provide novel insights concerning the regulation of glucose homeostasis and has direct and important clinical implications. We will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP (Endogenous Glucose Production) following SGLT2 inhibition.
      Contact
      210-567-6691
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Preservation of Beta Cell Function in pre-diabetes in subject with impaired...
      Protocol No.
      HSC20130414H
      Official Title
      Preservation of Beta Cell Function in pre-diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)
      Description
      This study will identify individuals who may have early signs of developing diabetes and understand how early treatment will help their body in controlling blood sugar levels and protecting function of their pancreas.
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   REGULATION OF HEPATIC AND PERIPHERAL GLUCOSE METABOLISM: Protocol VI. Effect...
      Protocol No.
      HSC20060251H
      Official Title
      REGULATION OF HEPATIC AND PERIPHERAL GLUCOSE METABOLISM: Protocol VI. Effect of Combined Reduction in Plasma FFA (with Acipimox) and Plasma Glucose (with Dapagliflozin) on Mitochondrial Dysfunction and Insulin Signaling/Sensitivity in T2DM
      Description
      Contact
      210-567-3208
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTION...
      Protocol No.
      HSC20160042H
      Official Title
      SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTION Significance - PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
      Description
      We will examine the contribution of the renal nerves to the stimulation of EGP (endogenous glucose production) following SGLT2 inhibition.
      Contact
      210-567-6691
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   SGLT2 Inhibition and Stimulation of Endogenous Glucose Production - PROTOCOL...
      Protocol No.
      HSC20150668H
      Official Title
      SGLT2 Inhibition and Stimulation of Endogenous Glucose Production - PROTOCOL 2: Elucidation of Mechanisms Responsible for the Increase in EGP Following SGLT2 Inhibition: Decrease in Plasma Glucose Conc or Change in Islet Hormone (Glucagon/Insulin) Secretion
      Description
      We will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP (Endogenous Glucose Production) following SGLT2 inhibition. In addition to providing novel insights concerning the regulation of glucose homeostasis, the present study has direct and important clinical implications.
      Contact
      210-567-6691
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Study of MLR 1023 (investigational drug for type 2 diabetes) in Adults with...
      Protocol No.
      HSC20170479H
      Official Title
      A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Add-on Study of MLR-1023 in Adults with Uncontrolled Type 2 Diabetes on Metformin Therapy
      Description
      This study is to evaluate the efficacy and safety of MLR-1023 (investigational drug for type 2 diabetes) in combination with metformin in subjects with uncontrolled Type 2 Diabetes Mellitus (T2DM).
      Contact
      210-567-6691
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness...
      Protocol No.
      HSC20130205H
      Official Title
      The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE Study)
      Description
      IF YOU ARE: Have diabetes for less than 5 years but otherwise healthy and Taking Metformin as your only diabetes medication, you may be eligible to join a clinical trial conducted by the Diabetes Division of the UTHSCSA at the Texas Diabetes Institute (TDI).
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Role of Glucose Mediated Glucose Uptake in the Pathogenesis of IFG and IGT
      Protocol No.
      HSC20130028H
      Official Title
      The Role of Glucose Mediated Glucose Uptake in the Pathogenesis of IFG and IGT
      Description
      quantitate: (i) whole body GMGU with the stepped hyperglycemic clamp and somatostatin infusion with and without replacement of basal insulin, (ii) insulin-mediated glucose uptake (IMGU) with stepped euglycemic insulin clamp, in IFG subjects and compare the results to IGT and NGT
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Type 1 Diabetes TrialNet: Natural History Study of the Development of Type 1...
      Protocol No.
      HSC20060084H
      Official Title
      Type 1 Diabetes TrialNet: Natural History Study of the Development of Type 1 Diabetes (Protocol TN-01)
      Description
      The goals of the TrialNet Natural History Study of the Development of T1D are to gain information about the pathogenesis and natural history of T1D and to facilitate the recruitment and assessment of individuals who might qualify for T1D prevention trials. Importantly, the information obtained from this study will serve to enable the development and implementation of prevention trials. Objectives: The overall objective of this study is to perform baseline and repeat assessments over time of the metabolic and immunologic status of individuals at risk for T1D in order: • To characterize their risk for developing T1D • To describe the pathogenetic evolution of T1D • To increase the understanding of pathogenetic factors involved in the development of T1D. Specific objectives 1.To determine the risk for the occurrence of T1D according to oral glucose tolerance tests (OGTT), C-peptide levels, biochemical autoantibodies (anti-GAD65, anti-ICA512 and IAA), islet cell autoantibodies (ICA), markers of cell-mediated immunity, and HLA genetic markers that are associated with risk for T1D. 2. To examine the accuracy of TrialNet risk assessment procedures for predicting future T1D. 3. To determine the prevalence of impaired glucose tolerance and ICA positivity in individuals with at least one positive biochemical autoantibody test. 4. To characterize the progression of immunologic abnormalities in the development of T1D by serially studying biochemical autoantibodies, ICA, and markers of cell-mediated immunity. 5. To characterize the progression of metabolic decompensation in the development of T1D by serially studying insulin, C-peptide and glucose levels, and to identify immunologic and other factors associated with this decompensation. 6. To determine the incidence of severe acute metabolic decompensation as the initial clinical presentation in individuals who have been identified as being at increased risk for T1D. 7. To identify individuals who qualify for TrialNet prevention trials for T1D. 8. To accrue additional information about immunologic and metabolic factors related to the pathogenesis of T1D by analyzing stored blood samples. The Immune Tolerance Network will function as a core laboratory for TrialNet for the development of specialized immunologic procedures. 9. To accrue additional information about genetic markers associated with risk for the development of T1D by analyzing stored blood samples. 10. For those who participated in the DPT-1 study, to examine associations of characteristics (e.g. demographics, immunologic, metabolic, etc.) assessed during the DPT-1 study with characteristics and outcomes assessed in TrialNet.
      Contact
      210-567-5284
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Vertebral Fracture Risk of Diabetic Latinos in San Antonio
      Protocol No.
      HSC20110495H
      Official Title
      Vertebral Fracture Risk of Diabetic Latinos in San Antonio
      Description
      A research study of spine (vertebral) fractures in Latinos and non-Latino whites with and without type 2 diabetes. The researchers hope to learn whether or not having type 2 diabetes puts Latinos at higher risk for having spine fractures, and whether Latinos are at greater risk than non-Latino whites for this type of injury. They also hope to learn whether there are differences between Latinos and non-Latino whites in areas such as bone density, bone quality, or severity of diabetes that might affect the risk of fracture in these groups.
      Contact
      210-567-5155
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Diagnostic

    •   Assessing Brain Injury Following Drowning Using Resting-state Functional...
      Protocol No.
      HSC20120268H
      Official Title
      Assessing Brain Injury Following Drowning Using Resting-state Functional Magnetic Resonance Imaging
      Description
      In a population of pediatric HIE due to nonfatal drowning, we hypothesize that neural system integrity as determined by functional brain imaging will be highly predictive of patients’ functional status as determined by quantitative clinical examination. This hypothesis will be tested using independent components analysis (ICA) of resting-state functional magnetic resonance imaging (fMRI) in a population of pediatric hypoxic-ischemic encephalophy (HIE) secondary to nonfatal drowning.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genomics of immune mediated diseases
      Protocol No.
      HSC20160018H
      Official Title
      Genomics of Immune Mediated Diseases
      Description
      New diseases of the immune system can be discovered by studying the genetic makeup of patients with a strong family history. In addition to providing a diagnosis, genetic studies can suggest better treatments in some cases. We are looking for children with immune mediated symptoms, including immune deficiency, inflammatory symptoms such as fever, and episodes of swelling, with at least one close relative (parent or sibling) who has the same symptom(s) and another who is not affected. Blood samples will be taken and analyzed for genetic differences.
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Ear, Nose and Throat

    •   Hereditary causes of atretic ear canals (absense of an ear canal)
      Protocol No.
      HSC20040104H
      Official Title
      Molecular Characterization of Individuals with Ear Canal Atresia
      Description
      The researchers hope to learn more about the causes of atretic ear canals (absence of an ear canal). We will be looking for abnormalities in the hereditary material (DNA) which could cause atretic ear canals. We hope our results will help people with this disorder in the future.
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Emergency Medicine

    •   Study of Tranexamic Acid During Air Medical Prehospital Transport Trail.
      Protocol No.
      HSC20150290H
      Official Title
      Study of Tranexamic acid during Air and ground Medical Prehospital transport (STAAMP) trial Phase 3 Multi-Center, Prospective, Randomized, Blinded, Controlled Interventional Trial
      Description
      Patients that are 18 years of age and older that are involved in a very serious accident where they are suspected of bleeding badly on the outside or suspected of bleeding on the inside. Their blood pressure may be low. Patients suspected of this will automatically be enrolled in the study by the Airlife Nurses. Patients get randomized to get the study medication or a placebo. The study drug helps stop bleeding and the placebo is salt water. Once patients get to the hospital they continue in the study and will have the option then to decide to continue in the study of not.
      Contact
      210-743-4130
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Family Health

    •   Illness representations in elders living in the United States with Multiple...
      Protocol No.
      HSC20160103H
      Official Title
      Illness Representations in Elders Living in the United States with Multiple Chronic Conditions: A Mixed Methods Study
      Description
      Multiple Chronic Conditions (MCC) are two or more long-lasting conditions that may be controlled but not cured. Illness representation (IL) is how a person feels about and manages their chronic condition. Coping procedures are actions taken to manage a condition and appraisal represents the evaluation of how one manages their condition. Understanding IL,coping procedures and appraisals may help to improve management of multiple chronic conditions.
      Contact
      210-291-7358
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Metformin and vaccine response in older adults
      Protocol No.
      HSC20180171H
      Official Title
      Metformin and vaccine response in older adults
      Description
      Older adults’ immune systems will weaken with age. Over time, it becomes more difficult to mount an adequate immune response to vaccines to protect against subsequent infections, such as pneumonia. This study will provide information on whether a treatment with metformin will improve ‘pneumonia’ vaccine responses in older adults. Participants will be followed for 3 months.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Genetics

    •   Genetic and Environmental Influences on Growth, Motor, Cognitive, Behavioral...
      Protocol No.
      HSC20090012H
      Official Title
      Genetic and Environmental Influences on Growth, Motor, Cognitive, Behavioral and Language Development of Premature Infants
      Description
      A research study to understand how genes and the environment affect premature birth and infant development.
      Contact
      210-567-5225
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Chromosome 18 Clinical Research Center.
      Protocol No.
      HSC20000318H
      Official Title
      The Chromosome 18 Clinical Research Center.
      Description
      To learn as much as possible about the medical and educational effects of a chromosome 18 deletion or duplication, and to learn about the genes that are duplicated or deleted.
      Contact
      210-567-5321
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Understanding Type and Quality of Relationships between Individuals with...
      Protocol No.
      HSC20070194H
      Official Title
      Understanding Type and Quality of Relationships between Individuals with Chromosome 18 Abnormalities and their Siblings
      Description
      Relationships between Individuals with Chromosome 18 Abnormalities and their Siblings
      Contact
      210-567-5321
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Healthy Subjects Needed

    •   Bariatric Surgeries and Glucose Metabolism
      Protocol No.
      HSC20180070H
      Official Title
      Bariatric Surgeries and Glucose Metabolism
      Description
      This research study is being performed to answer specific questions about changes in glucose metabolism after weight-loss surgery. Insulin is the main hormone that controls the level of glucose (sugar) in your blood. Two most commonly performed weight-loss surgeries (bariatric surgery), gastric bypass surgery and sleeve gastrectomy, improve glucose control in patients with type 2 diabetes before any weight loss happens. The amount of insulin that your body makes after eating is increased after these surgeries. Evidence suggests that these surgeries increase gut hormones, which in turn can increase insulin levels. One of the gut hormones is called GLP-1 or “glucagon-like peptide 1”. Another is called GIP or “glucose-dependent insulinotropic peptide”. This study will determine the effects of bariatric surgery on blood glucose levels and insulin response that are mediated by gut hormones as well as neural activity. You may qualify to take part in this research study if you are between 18 and 80 years of age and you either had weight loss surgery or because you are serving as a healthy volunteer who did not have any gut surgery (control subject).
      Contact
      210-567-4686
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Brain Oxygen Utilization: Methods Validation
      Protocol No.
      HSC20170187H
      Official Title
      Brain Oxygen Utilization: Methods Validation
      Description
      This study is being done to test a new method for measuring brain oxygen use (oxygen metabolism) that will be faster, cheaper and more widely available than the older method. The new method uses MRI (Magnetic resonance imaging) that developed by a research group in Johns Hopkins University. The older method uses PET (positron emission tomography), which has been recognized as the gold standard for over 30 years. This study will compare the two methods in healthy, normal people, to test whether they give the same values.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Canary Prostate Active Surveillance Study (PASS) (CTRC# 20080303H)
      Protocol No.
      HSC20080303H
      Official Title
      Canary Prostate Active Surveillance Study (PASS) (CTRC# 20080303H)
      Description
      All care participants receive is Standard of Care for Active Surveillance.  Research procedures include blood draw every 6 months for serum and plasma, urine collections, prostate tissue collection, Food & Supplement Use Questionnaire and the Health-Related Quality of Life Questionnaire.  Purpose of the PASS is to understand how prostate cancer behaves and to find unique biomarkers (substances in blood, urine or tissue which can indicate the presence of cancer) associated with prostate cancer
      Contact
      210-450-0705
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Class switching, somatic hypermutation and plasma cell differentiation in B...
      Protocol No.
      HSC20140234H
      Official Title
      Class switching, somatic hypermutation and plasma cell differentiation in B cells. [Title of overall grant: Healthy Volunteer Blood Donor Program]
      Description
      This research study will investigate how certain immune cells make antibodies. Blood donors needed to act as normal, healthy controls for lupus research study.
      Contact
      210-567-3956
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Donation of Blood for Pilot Research Studies
      Protocol No.
      HSC20010081H
      Official Title
      Donation of Blood for Pilot Research Studies
      Description
      Contact
      210-567-5532
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of a pancreas produced hormone (Glucagon) on adipose (fat) tissue.
      Protocol No.
      HSC20170682H
      Official Title
      EFFECT OF PHYSIOLOGIC HYPERGLUCAGONEMIA ON ADIPOCYTE METABOLISM
      Description
      You are asked to participate in this research study to investigate the effect of high levels of glucagon- a hormone produced by the pancreas, on insulin action, particularly in adipose (fat) tissue. Very little information is available concerning the effect of high levels of glucagon on insulin action, particularly on peripheral tissues, including fat tissue. The researchers hope to learn the cause of disease andmechanisms of metabolic interruption that is induced by high levels of glucagon in type 2 diabetes patients.
      Contact
      210-567-4686
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of mTOR Inhibition and other Metabolism Modulating Interventions on...
      Protocol No.
      HSC20120304H
      Official Title
      Effect of mTOR Inhibition and other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Fuctional Consequences.
      Description
      A research study of the mechanisms that are affected by the mTOR inhibition by Rapamycin. Rapamycin is a drug approved by the US Food and Drug Administration (FDA) for human use that has shown to increase lifespan in laboratory animals. In human medicine, Rapamycin is used is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. mTOR controls growth of cells in your body. Rapamycin reduced mTOR effects. The researchers hope to learn how mTOR inhibition affects humans by looking at how the immune system that is altered in normal aging and mTOR inhibition by Rapamycin. The information gained from these experiments will aid in understanding how mTOR inhibition works in humans and will provide new and important information on changes in age-related immune system regulation.
      Contact
      210-497-7279
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of the Diabetes Medication - Dapagiflozin on glucose use by the liver
      Protocol No.
      HSC20170214H
      Official Title
      Effect of Dapagiflozin on hepatic glucose metabolism: role of autonomic nervous system
      Description
      Dapagliflozin is a novel unique drug recently approved by the FDA for the treatment of type 2 diabetes. In previous studies, we found that in addition to lowering glucose sugar levels in the blood, dapagliflozin increases glucose sugar production by the liver and increases the rate of fat oxidationburning fat in the body. These actions of the drug decrease its effectivnessefficacy in lowering the blood sugar and increase the risk of complications. The aim of of the presentthis study is to understand the mechanism way by whichthat dapagliflozin causes the liver to increase sugar production and fat burning so that these actions, this allows us we can tothen develop methods to prevent them. You are being asked to be a participant in this study because you have type 2 diabetes and your blood sugar is not too high that requires treatment with medications. Or you do not have diabetes and the results of your tests will be used to compare to those with diabetes.
      Contact
      210-567-6710
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Establishing Community-Based Normal Distributions of Selected Urinary Biomarkers
      Protocol No.
      HSC20110312H
      Official Title
      Establishing Community-Based Normal Distributions of Selected Urinary Biomarkers
      Description
      This research study has been ongoing for 10 years and originally funded by the American Cancer Society.  For the past 3 years it has been funded by the National Cancer institute but with a different focus.  The three goals of this study are: To improve the accuracy of screening tests for the diagnosis of prostate cancer. Identify biomarkers that will predict how aggressive prostate cancer will be.  The tests currently in use for screening for prostate cancer are the PSA blood test and digital rectal examination (DRE) of the prostate.  When either or both of these tests are positive, a tissue biopsy of the prostate is recommended. The third goal is to provide accurate information about how rapidly prostate cancers will become worse.  To accomplish this we will study tissue and blood to identify proteins and genes that are present at high or low levels in prostate cancers that progress slowly versus those that progress more rapidly.
      Contact
      210-567-0178
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genetic and Environmental Influences on Growth, Motor, Cognitive, Behavioral...
      Protocol No.
      HSC20090012H
      Official Title
      Genetic and Environmental Influences on Growth, Motor, Cognitive, Behavioral and Language Development of Premature Infants
      Description
      A research study to understand how genes and the environment affect premature birth and infant development.
      Contact
      210-567-5225
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Human Innate Immunity and Tuberculosis
      Protocol No.
      HSC20170315H
      Official Title
      Human Innate Immunity and Tuberculosis
      Description
      Tuberculosis is an infection that primarily affects the lungs and causes fever and weight loss. While some people exposed to the tuberculosis (TB) bacteria develop the disease others do not. An important step in our understanding of these different responses is to measure the response of immune cells to infection with the TB bacteria. This study will request blood to be collected from healthy individuals and individuals who have had a positive test result for TB.
      Contact
      (210) 258-9577
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Immune Tests in Blood to Study Estrogens and Immune Co-Signal Effects on...
      Protocol No.
      HSC20110472H
      Official Title
      Immune Tests in Blood to Study Estrogens and Immune Co-Signal Effects on Immune Function in Age
      Description
      This study will help understand why immunity differs between men and women and how differences change over time. These data will help understand why women are more prone to autoimmunity, and how to use immune therapy effectively in different age groups and sexes. We will also test specific immune defects seen in mouse models of autoimmunity and cancer to determine if these defects also occur in humans.
      Contact
      450-1439
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Impact of disease associated noncoding polymorphisms on post-transcriptional...
      Protocol No.
      HSC20160074H
      Official Title
      Impact of Disease Associated Noncoding Polymorphisms on Post-Transcriptional Gene Regulation
      Description
      The purpose of this study is to identify genes and related RNA (ribonucleic acid) from healthy individuals, aged 18 to 35 years, that are expressed in our immune cells (i.e. the cells that fight infections in our body) that may be contributing to the risk of developing certain diseases like Crohn’s disease, atherosclerosis, and autoimmune diseases. This will be carried out by having study participants attend a short clinic visit that consists of a blood draw, a brief medical survey, and height/weight/blood pressure measurements.
      Contact
      210-601-6430
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Impact of the microbiome on diabetes health disparities
      Protocol No.
      HSC20170385H
      Official Title
      The Microbiome as a Potential Mediator of Diabetes Health Disparities
      Description
      This study will compare the gut microbiome of Mexican Americans with and without diabetes and determine the impact of other health disparity contributing factors on the microbiome composition. Links between the gut microbiome and health could provide novel prevention and intervention strategies for health disparities.
      Contact
      210-567-8345
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Inflammatory cytokine response to 12-week anaerobic and aerobic exercise: a...
      Protocol No.
      HSC20180166H
      Official Title
      Inflammatory cytokine response to 12-week anaerobic and aerobic exercise: a comparative study.
      Description
      Our purpose is to determine the effects 12-week anaerobic and aerobic trainings have on inflammatory cytokines. Our objective is to enroll 20 healthy men into a 12-week anaerobic or aerobic training protocol.
      Contact
      210-606-2437
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Inflammatory cytokine response to an acute bout of aerobic and anaerobic...
      Protocol No.
      HSC20180165H
      Official Title
      Inflammatory cytokine response to acute anaerobic and aerobic exercise: a comparative study
      Description
      Our purpose is to determine the effects acute bouts of anaerobic and aerobic trainings have on inflammatory cytokines. Our objective is to enroll 20 healthy men into an anaerobic or aerobic exercise bout.
      Contact
      210-606-2437
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Metabolism Study: Microbiome-Induced Insulin Resistance (Aim 2)
      Protocol No.
      HSC20130458H
      Official Title
      Mechanism of Microbiome-Induced Insulin Resistance in Humans (Aim 2)
      Description
      Aim 2: This outpatient study will evaluate how a probiotic (a type of good bacteria) or study medication (sevelamer)/placebo will affect the metabolism. Recent research suggests that people who are overweight or who have Type 2 diabetes have an elevation in the level of a substance called "endotoxin” in the blood. This study will examine if lowering the level of endotoxins will improve the way the body metabolizes (burns) sugars. We will enroll 3 populations: healthy people without diabetes who are lean and have no family history of diabetes; obese (BMI 30-37) non-diabetics without family history; and obese with Type 2 diabetes not taking insulin or metformin. Volunteers will be non-smokers between the ages of 18 and 65, sedentary lifestyle, stable body weight for >3 months, without recent heart attack or other clinical diagnosis not on stable treatment regimen.
      Contact
      210-450-0020
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Metformin and vaccine response in older adults
      Protocol No.
      HSC20180171H
      Official Title
      Metformin and vaccine response in older adults
      Description
      Older adults’ immune systems will weaken with age. Over time, it becomes more difficult to mount an adequate immune response to vaccines to protect against subsequent infections, such as pneumonia. This study will provide information on whether a treatment with metformin will improve ‘pneumonia’ vaccine responses in older adults. Participants will be followed for 3 months.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Pilot: Development and Optimization of MRI
      Protocol No.
      HSC20110120H
      Official Title
      Pilot: Development and Optimization of MRI
      Description
      The purpose of this study is to enable the development and optimization of non-invasive MRI pulse sequences, data acquisition and stimulation paradigms to be performed on members of the investigating team and in some occasions some external volunteers.
      Contact
      210-567-8181
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Prescription Opioid Research Study
      Protocol No.
      HSC20170141H
      Official Title
      Reducing the Abuse Liability of Prescription Opioids
      Description
      This is a study of new drug combinations to reduce the abuse potential of opioid analgesics. At the UT Pain Clinic the effect of these drug combinations on induced pain will be studied. Questions will be asked about how the drug affected you and whether you liked it.
      Contact
      210-562-4680
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Preservation of Beta Cell Function in pre-diabetes in subject with impaired...
      Protocol No.
      HSC20130414H
      Official Title
      Preservation of Beta Cell Function in pre-diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)
      Description
      This study will identify individuals who may have early signs of developing diabetes and understand how early treatment will help their body in controlling blood sugar levels and protecting function of their pancreas.
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Role of Lung Cells and Fluid in Tuberculosis
      Protocol No.
      HSC20170667H
      Official Title
      Human Alveolar Macrophages and Tuberculosis
      Description
      This work will increase understanding of M. tuberculosis interaction with human immune cells and/or lung fluid to aid in design of diagnostics and therapeutics. Human immune cells will be isolated from the blood and/or lung fluid, volunteers will not be exposed to M. tuberculosis.
      Contact
      210-258-9236
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Study of high fluoride toothpaste to prevent cavity
      Protocol No.
      HSC20160071H
      Official Title
      Assessment of Prevident Sodium Fluoride 1.1% toothpaste using an intra-oral remineralization-demineralization model
      Description
      The purpose of this study is to test if special toothpaste with higher level of fluoride than those in the pharmacy counters can repair cavities at early stage of formation more than the standard toothpastes in pharmacy counters.
      Contact
      210-834-7675
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Supporting Military Families with Young Children throughout the Deployment...
      Protocol No.
      HSC20150605H
      Official Title
      Supporting Military Families with Young Children throughout the Deployment Lifecycle: A Randomized Controlled Trial of Strong Families Strong Forces
      Description
      This research study will compare two ways of providing support to families with very young children when the family is going through a military deployment. The researchers hope to learn about the needs and challenges in parenting faced by Active Duty parents and spouses/partners who are coping with military-related separation and reintegration. Eligible participants are active duty military personnel and their spouse/partner who are stationed at Fort Hood, Texas; have at least one child 5 years or younger; spouse/partner will deploy within the next six months; and the deployment is expected to last at least three months.
      Contact
      254-288-1638
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue,...
      Protocol No.
      HSC20130013H
      Official Title
      Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue, Quality Of Life and Physical Function in Prostate Cancer Survivors (CTRC 12-0085)
      Description
      This study is designed as a cross-sectional, exploratory pilot study to examine the onset and progression of cancer-related fatigue in prostate cancer patients. The goal of this project is to report the effect of fatigue on quality of life and pilot a novel salivary biomarker to measure fatigue. One hundred men, diagnosed with prostate cancer and 200 men without prostate cancer will be recruited to participate in this study. Detailed medical and medication history will be reviewed to determine if subjects are eligible to participate in this study. All eligible participants will be recruited to participate in this study. All activities will be done during the patients regularly scheduled visit with their oncologist at the CTRC. Each subject will sign an informed consent form indicating their willingness to participate after which they will complete a battery of survey instruments and provide a 4 mL saliva sample. Saliva will be used to assess concentrations of a fatigue biomarkers in this study and banked for future research studies. The total length of time for study participation for each subject should be less than 1 hour.
      Contact
      210-567-0362
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Understanding the genetics of bipolar I disorder in adolescents
      Protocol No.
      HSC20150334H
      Official Title
      Application of induced pluripotent stem cells for the study of bipolar I disorder
      Description
      The purpose of this research is to develop a cell-based system to study adolescent bipolar I disorder to better understand genetic and epigenetic mechanisms associated with risk and develop new methods for treatment. We will perform MRI, neurocognitive and neuropsychiatric testing and draw blood.
      Contact
      210-258-9766
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Variable-Length Cognitive Processing Therapy for Combat-Related PTSD
      Protocol No.
      HSC20140324H
      Official Title
      Variable-Length Cognitive Processing Therapy for Combat-Related PTSD
      Description
      This STRONG STAR research study will determine the most effective length of treatment for Posttraumatic Stress Disorder (PTSD) and to determine who will benefit from shorter or longer courses of treatment. Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD that involves learning to recognize and challenge thoughts related to traumatic experiences. The normal course of treatment is 12 sessions, but participants may be treated for up to 24 sessions or until PTSD symptoms have reduced significantly, whichever comes first. Eligible participants are active duty OIF/OEF/OND veterans with PTSD who are stationed at Fort Hood.
      Contact
      254-553-1871
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Heart, Vascular and Blood

    •   Alternative Method for the Minimally Invasive Treatment of Persistent Atrial...
      Protocol No.
      HSC20160269H
      Official Title
      Amaze Trial: Left Atrial Appendage Ligation with the Lariat® Suture Delivery System as Adjunctive Therapy to Pulmonary Vein Isolation (PVI) for Persistent or Longstanding Persistent Atrial Fibrillation
      Description
      Symptomatic persistent atrial fibrillation lasting for over seven days at a time can be a difficult heart problem to treat effectively. Current catheter ablation approaches do not always achieve long-term success in patients. Sometimes, combined approaches of catheter ablation and procedures requiring surgical incisions into the chest are performed for patients with symptomatic persistent atrial fibrillation. A new study called the aMAZE trial is studying the benefit of performing ligation of a heart structure called the left atrial appendage using a minimally invasive method. Combining this method with pulmonary vein isolation using traditional catheter ablation may lead to better results in patients with persistent or long-standing persistent atrial fibrillation. The aMAZE trial is enrolling eligible patients to undergo percutaneous left atrial appendage suture ligation and then catheter ablation for their atrial fibrillation. Patients will be followed to analyze the benefits, complications, and overall outcomes of the procedures and to see if this new procedure may provide a better alternative for patients with persistent atrial fibrillation compared to existing methods that are currently used.
      Contact
      210-567-8692
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Expression of Interleukin-18, IL-18 Receptors and IL-18 Binding Protein in...
      Protocol No.
      HSC20050198H
      Official Title
      Expression of Interleukin-18, IL-18 Receptors and IL-18 Binding Protein in Myocardial Tissue
      Description
      Contact
      (210) 567-2878
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genetics of Coronary Artery Disease in Alaska Natives
      Protocol No.
      HSC20000388H
      Official Title
      Genetics of Coronary Artery Disease in Alaska Natives
      Description
      Why some people get heart disease and others do not.
      Contact
      258-9710
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Identification and Analysis of Immunomodulatory Molecules From Leukocytes in...
      Protocol No.
      HSC20040268H
      Official Title
      Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients with Hematologic Disorders and Healthy Volunteers
      Description
      Contact
      617-5300 x16777
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   IL-18 Expression in Human Cardiovascular Tissue and its Role in Left...
      Protocol No.
      HSC20070031H
      Official Title
      IL-18 Expression in Human Cardiovascular Tissue and its Role in Left Ventricular Hypertrophy and Congestive Heart Failure
      Description
      Contact
      210-567-2878
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Illness representations in elders living in the United States with Multiple...
      Protocol No.
      HSC20160103H
      Official Title
      Illness Representations in Elders Living in the United States with Multiple Chronic Conditions: A Mixed Methods Study
      Description
      Multiple Chronic Conditions (MCC) are two or more long-lasting conditions that may be controlled but not cured. Illness representation (IL) is how a person feels about and manages their chronic condition. Coping procedures are actions taken to manage a condition and appraisal represents the evaluation of how one manages their condition. Understanding IL,coping procedures and appraisals may help to improve management of multiple chronic conditions.
      Contact
      210-291-7358
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   International Study of Comparative Health Effectiveness with Medical and...
      Protocol No.
      HSC20120218H
      Official Title
      International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA)
      Description
      A research study of how to help people who have narrowed heart arteries due to the buildup of cholesterol. When a heart artery narrows some part of the heart may not receive enough blood to work normally. Doctors refer to this problem as ischemia and they have two standard ways to treat it. 1. One way uses medicines and lifestyle changes to control symptoms (angina or chest pain) and reduce serious events (such as heart attack). Medicines that are routinely used for this include aspirin and cholesterol lowering drugs. Lifestyle changes may include changing what and how much you eat, exercising more, and not smoking. 2. Another way uses a procedure to open artery narrowings with a balloon and or heart surgery to bypass the problem artery. Stents are small metal mesh tubes that are placed into heart arteries to prop them open. Bypass is a surgical operation to insert a blood vessel from your leg or chest to go around the blocked area in the heart artery. Doctors and patients make the choice between stents and bypass surgery based on which procedure is thought to provide the better result. Both treatments #1 and #2 are used by doctors around the world and are not experimental. The researchers hope to learn which one saves more lives and prevents more heart attacks. We will do this by comparing the two.
      Contact
      (210) 617-5300 ext. 4654
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Multicenter Registry for Peripheral Arterial Disease Interventions and...
      Protocol No.
      HSC20130375H
      Official Title
      Multicenter Registry for Peripheral Arterial Disease Interventions and Outcomes (XL PAD Registry)
      Description
      Excellence in Peripheral arterial disease (XL PAD) is an observational study to evaluate the “real world” effectiveness of using stent and non-stent based therapies among Peripheral Arterial Disease (Claudication symptoms or pain in legs due to blockages of blood supply to the legs) patients treated with Percutaneous Intervention (Balloon angioplasty or stenting) primarily focusing on Superficial Femoral Artery interventions.
      Contact
      210-567-2106
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Neutrophil Activation of the Oxidative Burst
      Protocol No.
      HSC19940484H
      Official Title
      Neutrophil Activation of the Oxidative Burst
      Description
      This study is a research project on the antibacterial function of white blood cells. We hope to learn how white blood cells work to prevent infection and how they respond after infection occurs. You are asked to participate in this research study because laboratory analysis of your white blood cell function in the test tube will be an important part of our attempts to improve understanding how these cells respond to infections.
      Contact
      210-562-4010
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Prehospital Remote Ischemic Cardiac Conditioning Trial
      Protocol No.
      HSC20120336H
      Official Title
      Prehospital Remote Ischemic Cardiac Conditioning Trial
      Description
      A research study of blood pressure and heart attacks. This research may provide information whether the blood pressure cuff procedure can protect the heart during a heart attack by comparing the tests that will be run at the hospital between those who had the cuff inflated to those who did not.
      Contact
      210-567-7598
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Prospective Cohort Study of Cytokines in Pneumonia.
      Protocol No.
      HSC20100463H
      Official Title
      Prospective Cohort Study of Cytokines in Pneumonia.
      Description
      A research study of the effects of cholesterol-lowering medications, called statins, on pneumonia. The researchers hope to learn if there are any effects, good or bad, from taking a statin when you have pneumonia.
      Contact
      617-5300, ext 15413
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Role of IL-18 in Aortic Aneurysms
      Protocol No.
      HSC20110130H
      Official Title
      Role of IL-18 in Aortic Aneurysms
      Description
      To investigate the expression levels of IL-18 (an inflammatory marker), it''s receptors IL-18Ra and b, and its natural inhibitor IL-18 binding protein (IL-18BP) in aortic aneurysms.
      Contact
      210-567-2878
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Severe Chronic Neutropenia International Registry Protocol
      Protocol No.
      HSC19960054H
      Official Title
      Severe Chronic Neutropenia International Registry Protocol
      Description
      Contact
      210-704-3405
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Immune System

    •   Genomics of immune mediated diseases
      Protocol No.
      HSC20160018H
      Official Title
      Genomics of Immune Mediated Diseases
      Description
      New diseases of the immune system can be discovered by studying the genetic makeup of patients with a strong family history. In addition to providing a diagnosis, genetic studies can suggest better treatments in some cases. We are looking for children with immune mediated symptoms, including immune deficiency, inflammatory symptoms such as fever, and episodes of swelling, with at least one close relative (parent or sibling) who has the same symptom(s) and another who is not affected. Blood samples will be taken and analyzed for genetic differences.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Varicella zoster vaccine study (VERVE)
      Protocol No.
      HSC20160085H
      Official Title
      The Safety and Effectiveness of the VaricElla zosteR VaccinE (VERVE) in Anti-TNF Users
      Description
      This study will test the effectiveness of Zostavax, the shingles vaccine, in preventing shingles among people with arthritis who are taking biologic treatments, which include Remicade, Enbrel, Humira, Cimzia, or Simponi. Shingles causes painful blisters along the course of a nerve branches and in some cases may cause eye damage. Preventing shingles with vaccination is the focus of this clinical trial that will evaluate the safety and effectiveness of Zostavax. Patients with inflammatory arthritis taking biologics will be randomized to receive Zostavax or placebo. Six weeks later, they will return to see if they have developed defenses to the varicella-zoster virus, through blood analysis. The findings of the study will be used to formulate recommendations for the use of Zostavax in people receiving biologic therapy in patients with arthritis.
      Contact
      210-567-6853
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Infections/ Infectious Diseases

    •   NF-Kappa B Activation by NADPH Oxidases (Project of a program entitled...
      Protocol No.
      HSC19949484H
      Official Title
      NF-Kappa B Activation by NADPH Oxidases (Project of a program entitled "Nuclear Factor Kappa B, Oxidative Stress and Aging)
      Description
      This study is a research project on the antibacterial function of white blood cells. We hope to learn how white blood cells work to prevent infection and how they respond after infection occurs.
      Contact
      210-562-4010
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Lungs, Breathing and Bronchial

    •   52 week study on the safety and effect of two investigational inhalers on...
      Protocol No.
      HSC20160421H
      Official Title
      A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD PT009003-00
      Description
      This study will evaluate moderate to severe COPD that remains symptomatic despite treatment with one or more inhaled maintenance medications.
      Contact
      210-617-5256
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   CF-FC Study: A Long-Term Prospective Observational Safety Study of the...
      Protocol No.
      HSC20120208H
      Official Title
      CF-FC Study: A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors CFFC-OB-11
      Description
      Registry Primary Objectives: The primary objective of this study is to quantify over a 10-year period the incidence of fibrosing colonopathy in US patients with CF treated with specific PERT (CREON®, PANCREAZE®, or ZENPEP®). Secondary Objectives: The secondary objective of this study is to quantify the association between potential risk factors and the development of fibrosing colonopathy in patients with CF.
      Contact
      210-704-4447
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Illness representations in elders living in the United States with Multiple...
      Protocol No.
      HSC20160103H
      Official Title
      Illness Representations in Elders Living in the United States with Multiple Chronic Conditions: A Mixed Methods Study
      Description
      Multiple Chronic Conditions (MCC) are two or more long-lasting conditions that may be controlled but not cured. Illness representation (IL) is how a person feels about and manages their chronic condition. Coping procedures are actions taken to manage a condition and appraisal represents the evaluation of how one manages their condition. Understanding IL,coping procedures and appraisals may help to improve management of multiple chronic conditions.
      Contact
      210-291-7358
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Microparticles Generated by Cardiopulmonary Bypass.
      Protocol No.
      HSC20120097H
      Official Title
      Microparticles Generated by Cardiopulmonary Bypass.
      Description
      To obtain peripheral blood from normal volunteers to study the generation of microparticles.
      Contact
      210-562-5816
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   North American Cystic Fibrosis Foundation Patient Registry
      Protocol No.
      HSC20020383H
      Official Title
      North American Cystic Fibrosis Foundation Patient Registry
      Description
      By examining the health status of patients with cystic fibrosis annually, valuable information has (and will continue) to be gained about the trends in nutrition, medical problems, lung transplantation and bacterial colonization in patients with cystic fibrosis. Collection and analysis of this information (which is collected on every CF patient in North America) allows CF care teams to improve in their knowledge of the disease and to change the way they care for patients with CF appropriately.
      Contact
      562-5830
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Prospective Cohort Study of Cytokines in Pneumonia.
      Protocol No.
      HSC20100463H
      Official Title
      Prospective Cohort Study of Cytokines in Pneumonia.
      Description
      A research study of the effects of cholesterol-lowering medications, called statins, on pneumonia. The researchers hope to learn if there are any effects, good or bad, from taking a statin when you have pneumonia.
      Contact
      617-5300, ext 15413
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study...
      Protocol No.
      HSC20170199H
      Official Title
      Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study in idiopathic pulmonary fibrosis
      Description
      To reduce the abundance of pro-inflammatory cells over baseline within subjects following treatment with dasatinib and quercetin
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Men's Health

    •   Biomarkers and clinical parameters associated with Gleason score upgrading...
      Protocol No.
      HSC20140367H
      Official Title
      Biomarkers and clinical parameters associated with Gleason score upgrading (CTRC# 14-0031)
      Description
      This study involves the collection of blood samples by finger stick, heel stick, ear stick, or venipuncture from unhealthy adults, pregnant adults or children.  Considering the person’s age, weight, and health, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected the blood samples intended for this study are minimal risk.
      Contact
      210-567-0178
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Chemical and Environmental Intolerances
      Protocol No.
      HSC20150821H
      Official Title
      Toxicant Induced Loss of Tolerance: Research and Education
      Description
      The purpose of this research is to identify individuals who suffer from chemical intolerances and to look for potential environmental triggers that may be in their homes. Our goal is to offer practical solutions and determine if symptoms improve after implementing our team''s recommendations.
      Contact
      210-827-7681
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of mTOR Inhibition and other Metabolism Modulating Interventions on...
      Protocol No.
      HSC20120304H
      Official Title
      Effect of mTOR Inhibition and other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Fuctional Consequences.
      Description
      A research study of the mechanisms that are affected by the mTOR inhibition by Rapamycin. Rapamycin is a drug approved by the US Food and Drug Administration (FDA) for human use that has shown to increase lifespan in laboratory animals. In human medicine, Rapamycin is used is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. mTOR controls growth of cells in your body. Rapamycin reduced mTOR effects. The researchers hope to learn how mTOR inhibition affects humans by looking at how the immune system that is altered in normal aging and mTOR inhibition by Rapamycin. The information gained from these experiments will aid in understanding how mTOR inhibition works in humans and will provide new and important information on changes in age-related immune system regulation.
      Contact
      210-497-7279
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Home based exercise and men with prostate cancer
      Protocol No.
      HSC20160604H
      Official Title
      Impact of a home-based exercise program on prognostic biomarkers in men with prostate cancer
      Description
      The purpose of this study is to determine the benefits of a home based exercise program on cancer progression in men with prostate cancer
      Contact
      210-567-0362
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Impact of Yoga as Complementary Therapy on Quality of Live, Pro-Inflammatory...
      Protocol No.
      HSC20150406H
      Official Title
      Impact of Yoga as Complementary Therapy on Quality of Live, Pro-Inflammatory and Cellular Immune Biomarkers in Patients Undergoing Radical Prostatectomy: A Pilot Randomized Controlled Trial (CTRC# 15-0003)
      Description
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue,...
      Protocol No.
      HSC20130013H
      Official Title
      Symptom Management in Prostate Cancer Survivors: Cancer-Related Fatigue, Quality Of Life and Physical Function in Prostate Cancer Survivors (CTRC 12-0085)
      Description
      This study is designed as a cross-sectional, exploratory pilot study to examine the onset and progression of cancer-related fatigue in prostate cancer patients. The goal of this project is to report the effect of fatigue on quality of life and pilot a novel salivary biomarker to measure fatigue. One hundred men, diagnosed with prostate cancer and 200 men without prostate cancer will be recruited to participate in this study. Detailed medical and medication history will be reviewed to determine if subjects are eligible to participate in this study. All eligible participants will be recruited to participate in this study. All activities will be done during the patients regularly scheduled visit with their oncologist at the CTRC. Each subject will sign an informed consent form indicating their willingness to participate after which they will complete a battery of survey instruments and provide a 4 mL saliva sample. Saliva will be used to assess concentrations of a fatigue biomarkers in this study and banked for future research studies. The total length of time for study participation for each subject should be less than 1 hour.
      Contact
      210-567-0362
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study...
      Protocol No.
      HSC20170199H
      Official Title
      Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study in idiopathic pulmonary fibrosis
      Description
      To reduce the abundance of pro-inflammatory cells over baseline within subjects following treatment with dasatinib and quercetin
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Minority Studies

    •   Vertebral Fracture Risk of Diabetic Latinos in San Antonio
      Protocol No.
      HSC20110495H
      Official Title
      Vertebral Fracture Risk of Diabetic Latinos in San Antonio
      Description
      A research study of spine (vertebral) fractures in Latinos and non-Latino whites with and without type 2 diabetes. The researchers hope to learn whether or not having type 2 diabetes puts Latinos at higher risk for having spine fractures, and whether Latinos are at greater risk than non-Latino whites for this type of injury. They also hope to learn whether there are differences between Latinos and non-Latino whites in areas such as bone density, bone quality, or severity of diabetes that might affect the risk of fracture in these groups.
      Contact
      210-567-5155
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Mouth and Tooth

    •   Incidence and Factors Associated with the Development and Severity of Oral...
      Protocol No.
      HSC20050218H
      Official Title
      Incidence and Factors Associated with the Development and Severity of Oral Mucositis in Patients Undergoing High Dose Chemotherapy and Peripheral Stem Cell Transplantation (CTRC# 20050218H)
      Description
      Our study intends to evaluate prospectively the incidence and severity of oral mucositis in patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation, as well as to evaluate the potential influence of nutritional-, physical-, and transplant-related factors associated with the development of this complication and its grade of involvement. Research plan: This is a prospective cohort study with an observational basis that involves all of the patients undergoing high-dose chemotherapy and peripheral blood stem cell transplantation at the Audie L. Murphy VA Hospital Bone Marrow Transplant Unit and at the University Hospital Bone Marrow Transplant Unit. We expect to enroll 400 patients during a 5-year period. Methods: In order to answer the study questions, subjects will be assessed several times during the study period. The study involves a multidisciplinary group that will be evaluating and following the subjects. A baseline will be established by a physician and a nutritionist before the subjects start the high-dose chemotherapy regimen. The subjects will be followed with oral evaluations 3 times per week, beginning on the day of the transplant and ending when mucositis resolves, or the patient is discharged home, or 30 days post-transplant, whichever occurs first. At day 15 post-transplant, patients will be evaluated for the second time by the nutritionist. Further information such as blood values, use of medications and treatment complications, will be obtained by daily chart review.  
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Rechargeable Infection-responsive Anticandidal Denture Materials
      Protocol No.
      HSC20120163H
      Official Title
      Rechargeable Infection-responsive Anticandidal Denture Materials
      Description
      To test the anticandidal drug binding and release kinetics as well as the cytotoxicities of the proposed long-term anticandidal denture materials
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Role of Dentin Growth Factors in the Induction of an Odontoblastic Phenotype...
      Protocol No.
      HSC20080148H
      Official Title
      Role of Dentin Growth Factors in the Induction of an Odontoblastic Phenotype in Stem Cells found in the Apical Papilla Formerly "Growth Factors that induce Odontoblastic Differentiation in Two Different Populations of Oral Stem Cells"
      Description
      The purpose of this study is to develop a culture media for stem cells found in the apical papilla of human molars and induce odontoblastic differentiation by treatment with factors found in dentin.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Studies on Normal and Inflamed Dental Pulp. Subtitle: "NPY Regulation of...
      Protocol No.
      HSC20020071H
      Official Title
      Studies on Normal and Inflamed Dental Pulp. Subtitle: "NPY Regulation of Peripheral Human Nociceptors and Pain" and "peripheral Mechanisms of Opioid Analgesia".Subtitle: "Cannabinoid-Induced Desensitization of TRPV1 Receptors" Subtitle: Adrenergic Modulation of Trigeminal Nociceptors. Subtitle: Estrogen Modulation of Human Nociceptors
      Description
      A research study about the effect of medicines on nerves in teeth and how they react to inflammation.
      Contact
      210-567-3388
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Replacement With a Dental Implant: A Five-Year Study Comparing...
      Protocol No.
      HSC20150705H
      Official Title
      Immediate Placement of the Straumann® Bone Level Tapered Implant with Early Loading in Single Tooth Gaps in the Maxilla and Mandible Compared to Delayed Placement
      Description
      Two different methods of using a dental implant will be compared, (1) the implant is placed immediately after tooth extraction and (2) the implant is placed after healing. Also, the effectiveness of the implant will be evaluated over a 5-year period.
      Contact
      210-776-6720
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Muscle, Bone and Cartilage

    •   Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with...
      Protocol No.
      HSC20170289H
      Official Title
      A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY AND OPEN-LABEL EXTENSION
      Description
      The main goals of this study are to obtain additional information on whether the actions of ataluren can slow disease progression
      Contact
      210-567-8222
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Varicella zoster vaccine study (VERVE)
      Protocol No.
      HSC20160085H
      Official Title
      The Safety and Effectiveness of the VaricElla zosteR VaccinE (VERVE) in Anti-TNF Users
      Description
      This study will test the effectiveness of Zostavax, the shingles vaccine, in preventing shingles among people with arthritis who are taking biologic treatments, which include Remicade, Enbrel, Humira, Cimzia, or Simponi. Shingles causes painful blisters along the course of a nerve branches and in some cases may cause eye damage. Preventing shingles with vaccination is the focus of this clinical trial that will evaluate the safety and effectiveness of Zostavax. Patients with inflammatory arthritis taking biologics will be randomized to receive Zostavax or placebo. Six weeks later, they will return to see if they have developed defenses to the varicella-zoster virus, through blood analysis. The findings of the study will be used to formulate recommendations for the use of Zostavax in people receiving biologic therapy in patients with arthritis.
      Contact
      210-567-6853
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Vertebral Fracture Risk of Diabetic Latinos in San Antonio
      Protocol No.
      HSC20110495H
      Official Title
      Vertebral Fracture Risk of Diabetic Latinos in San Antonio
      Description
      A research study of spine (vertebral) fractures in Latinos and non-Latino whites with and without type 2 diabetes. The researchers hope to learn whether or not having type 2 diabetes puts Latinos at higher risk for having spine fractures, and whether Latinos are at greater risk than non-Latino whites for this type of injury. They also hope to learn whether there are differences between Latinos and non-Latino whites in areas such as bone density, bone quality, or severity of diabetes that might affect the risk of fracture in these groups.
      Contact
      210-567-5155
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Nervous System

    •   A Randomized, Placebo-Controlled Trial to evaluate Lacosamide (Vimpat) as...
      Protocol No.
      HSC20150642H
      Official Title
      A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy And Safety of Lacosamide As Adjunctive Therapy For Uncontrolled Primary Generalized Tonic-Clonic Seizures In Subjects With Idiopathic Generalized Epilepsy
      Description
      This study seeks to evaluate the safety and efficacy of Lacosamide (VImpat) as an add-on therapy for patients with Grand Mal/Generalized Tonic-Clonic seizures (GTCS), already taking 1-2 Anti-Epileptic medications and still experiencing 1 GTCS every 4-6 weeks.
      Contact
      210-567-8222
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   A study of a new medicine for the treatment of...
      Protocol No.
      HSC20170700H
      Official Title
      A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Safety, and Efficacy Study of SHP465 in Children Aged 6-12 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)
      Description
      Children aged 6 to 12 years of age will have an evaluation to determine if they have ADHD. They then will be selected at random (like a flip of a coin) to either receive a medicine for ADHD (SHP465) or a placebo (an empty pill) for four weeks.
      Contact
      210-450-8405
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   A study of a new medicine for the treatment of...
      Protocol No.
      HSC20170701H
      Official Title
      A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactivity Disorder
      Description
      Children aged 4 to 12 years of age will have an evaluation to determine if they have ADHD. This study will be using an investigational drug (SHP465) for the treatment of ADHD. Participation in this study will last about 52 weeks.
      Contact
      210-450-8405
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Changes in Gait Associated with Arm Swing Post Botulinum Toxin Injection in...
      Protocol No.
      HSC20090190H
      Official Title
      Changes in Gait Associated with Arm Swing Post Botulinum Toxin Injection in Adults with Spastic Hemiparesis
      Description
      By evaluating hemiparetic stroke patients with upper extremity spasticity, we will assess the impact of improved arm range of motion that allows for arm swing during walking, on overall gait biomechanics, symmetry and energy requirements
      Contact
      210-567-5347
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Efficacy and Safety of Eslicarbazepine Acetate as an add-on to Levetiracetam...
      Protocol No.
      HSC20170406H
      Official Title
      Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects with Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial
      Description
      The first purpose is to evaluate the safety, effectiveness and tolerability (how well patients are able to take the study drug without serious side effects) of eslicarbazepine acetate (ESL) when given with levetiracetam or lamotrigine as a first option of treatment to those with partial-onset seizures who have not taken any previous treatments together for their partial-onset seizures. The second purpose of this research study is to evaluate the safety, effectiveness and tolerability (how well patients are able to take the study drug without serious side effects) of eslicarbazepine acetate (ESL) when taken in combination with a stable dose of 1-2 medications that have been taken for at least one month to those who have already been given combination treatments for their for partial-onset seizures in the past.
      Contact
      210-567-8222
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Functional Connectivity in Partial Neocortical Epilepsy
      Protocol No.
      HSC20110063H
      Official Title
      Functional Connectivity in Partial Neocortical Epilepsy
      Description
      Our overall goal is to noninvasively examine how epilepsy results from brain reorganization after stroke, focusing on changes in connectivity and excitability. We will test the hypothesis that the seizure onset zone (SOZ), the region in the brain where seizure activity originates, is reorganized differently after stroke. We will use three populations of patients in our studies: Population 1: Patients with neocortical epilepsy of different etiologies including stroke; Population 2: Patients with past stroke, without epilepsy; Population 3: Age and health matched normal controls. The following specific aim will be pursued: To noninvasively study network reorganization that underlies epileptogenesis after cortical motor stroke. We hypothesize that the seizure onset zone (SOZ), where seizure activity originates, undergoes a different reorganization after stroke compared to seizure-neutral post-stroke tissue. We will use functional connectivity, which refers to how different regions of the brain are linked to each other and as measured using non-invasive MRI techniques, as a measure of circuit organization. We will compare the connectivity patterns of a population of patients who already have post-stroke epilepsy at the onset of the study with several patient groups including: patients with epilepsy of other etiologies, patients with chronic stroke without epilepsy, as well as with normal controls. A subtractive analysis will allow us to identify post-stroke epilepsy-specific connectivity changes. To accomplish this goal, we will measure the connectivity between regions of interest (ROI) in the peri-infarct zone (PIZ), which is where seizures are presumed to start from, and other regions in the cortical motor/sensory network. When possible, we will determine the location of the seizure onset zone (SOZ) and use it as a ROI for this analysis. In summary, using rsfMRI, we will measure functional connectivity of post-stroke brain motor networks and identify changes that could be linked to epilepsy. Our investigations could contribute to a better in vivo understanding of epilepsy-related changes after stroke, and may help develop biomarkers for post-stroke epileptogenesis.
      Contact
      210-567-8229
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genetics of Bipolar Disorder in Latino Populations
      Protocol No.
      HSC20050224H
      Official Title
      Genetics of Bipolar Disorder in Latino Populations
      Description
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Illness representations in elders living in the United States with Multiple...
      Protocol No.
      HSC20160103H
      Official Title
      Illness Representations in Elders Living in the United States with Multiple Chronic Conditions: A Mixed Methods Study
      Description
      Multiple Chronic Conditions (MCC) are two or more long-lasting conditions that may be controlled but not cured. Illness representation (IL) is how a person feels about and manages their chronic condition. Coping procedures are actions taken to manage a condition and appraisal represents the evaluation of how one manages their condition. Understanding IL,coping procedures and appraisals may help to improve management of multiple chronic conditions.
      Contact
      210-291-7358
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Macrophage-mediated gene delivery of neurotrophic factors for Parkinson''s...
      Protocol No.
      HSC20120184H
      Official Title
      Macrophage-mediated gene delivery of neurotrophic factors for Parkinson''s disease
      Description
      Contact
      210-567-4627
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Nutrition

    •   Illness representations in elders living in the United States with Multiple...
      Protocol No.
      HSC20160103H
      Official Title
      Illness Representations in Elders Living in the United States with Multiple Chronic Conditions: A Mixed Methods Study
      Description
      Multiple Chronic Conditions (MCC) are two or more long-lasting conditions that may be controlled but not cured. Illness representation (IL) is how a person feels about and manages their chronic condition. Coping procedures are actions taken to manage a condition and appraisal represents the evaluation of how one manages their condition. Understanding IL,coping procedures and appraisals may help to improve management of multiple chronic conditions.
      Contact
      210-291-7358
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Other

    •   A Comparison of Web-Prolonged Exposure and Present-Centered Therapy for PTSD
      Protocol No.
      HSC20150392H
      Official Title
      A Comparison of Web-Prolonged Exposure (Web-PE) and Present-Centered Therapy for PTSD among Active-Duty Military Personnel and Veterans: Efficacy and Biological Mechanisms
      Description
      This STRONG STAR study evaluates how 10 sessions of an internet-delivered treatment, Web-PE, compare to 10 sessions of a therapist-delivered treatment, PCT in the treatment of PTSD. The project will also evaluate if changes in PTSD symptoms are linked to changes in stress hormones. Eligible participants are active duty military personnel with PTSD who have deployed since 9/11 and who are stationed at Fort Hood, Texas.
      Contact
      254-449-3617
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   An Open-Trial of Web-Prolonged Exposure (Web-PE) among Active-Duty Military...
      Protocol No.
      HSC20170600H
      Official Title
      An Open-Trial of Web-Prolonged Exposure (Web-PE) among Active-Duty Military Personnel and Veterans
      Description
      The purpose of this study is to improve access to treatment for posttraumatic stress disorder (PTSD) by evaluating whether 10 sessions of PE delivered via the Internet over 8 weeks (Web-PE) is effective in reducing PTSD symptoms. Eligible participants are active duty military personnel and veterans with PTSD who have deployed since 9/11. www.clinicaltrials.gov search "NCT03337750"
      Contact
      254-245-9743
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   ARST1321 - Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue...
      Protocol No.
      HSC20150224X
      Official Title
      ARST1321 - Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) (CTMS# 14-0043)
      Description
      ARST1321
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Bariatric Surgeries and Glucose Metabolism
      Protocol No.
      HSC20180070H
      Official Title
      Bariatric Surgeries and Glucose Metabolism
      Description
      This research study is being performed to answer specific questions about changes in glucose metabolism after weight-loss surgery. Insulin is the main hormone that controls the level of glucose (sugar) in your blood. Two most commonly performed weight-loss surgeries (bariatric surgery), gastric bypass surgery and sleeve gastrectomy, improve glucose control in patients with type 2 diabetes before any weight loss happens. The amount of insulin that your body makes after eating is increased after these surgeries. Evidence suggests that these surgeries increase gut hormones, which in turn can increase insulin levels. One of the gut hormones is called GLP-1 or “glucagon-like peptide 1”. Another is called GIP or “glucose-dependent insulinotropic peptide”. This study will determine the effects of bariatric surgery on blood glucose levels and insulin response that are mediated by gut hormones as well as neural activity. You may qualify to take part in this research study if you are between 18 and 80 years of age and you either had weight loss surgery or because you are serving as a healthy volunteer who did not have any gut surgery (control subject).
      Contact
      210-567-4686
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Chemical and Environmental Intolerances
      Protocol No.
      HSC20150821H
      Official Title
      Toxicant Induced Loss of Tolerance: Research and Education
      Description
      The purpose of this research is to identify individuals who suffer from chemical intolerances and to look for potential environmental triggers that may be in their homes. Our goal is to offer practical solutions and determine if symptoms improve after implementing our team''s recommendations.
      Contact
      210-827-7681
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for...
      Protocol No.
      HSC20140055H
      Official Title
      Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for Combat-Related PTSD
      Description
      This STRONG STAR research study will examine effective ways of delivering Cognitive Processing Therapy (CPT) for combat-related posttraumatic stress disorder (PTSD). CPT involves learning to recognize and challenge thoughts related to a traumatic experience and is typically done through face-to-face sessions in a mental health clinic. However, traveling into a clinic can be a potential barrier for some people. The goal of this study is to evaluate the effectiveness of administering CPT in one of the following treatment settings: 1) face-to-face in a clinic office, 2) face-to-face in the home setting, or 3) through telehealth (i.e., video sessions on your computer) in the home setting. Eligible participants are OIF/OEF/OND veterans with PTSD who reside in the San Antonio area.
      Contact
      210-562-6727
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Cognitive-Behavioral Therapy for Posttraumatic Headache
      Protocol No.
      HSC20140339H
      Official Title
      CAP - Consortium to Alleviate PTSD - STVHCS Project 7 entitled -Randomized Clinical Trial of Cognitive-Behavior Therapy for Posttraumatic Headache-
      Description
      This study will evaluate whether a leading cognitive behavioral therapy for migraine headaches is effective with posttraumatic headaches (PTHA) for those who also have symptoms of posttraumatic stress (PTS) or posttraumatic stress disorder (PTSD). Investigators also seek to determine if treatment for PTHA also alleviates symptoms of PTS/PTSD, and whether treatment for PTS/PTSD might also alleviate headache symptoms. Eligible participants are OIF/OEF/OND veterans with posttraumatic headache following a head injury and co-occurring symptoms of PTS/PTSD who reside in the San Antonio area.
      Contact
      210-562-6737
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Efficacy and Safety of Eslicarbazepine Acetate as an add-on to Levetiracetam...
      Protocol No.
      HSC20170406H
      Official Title
      Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects with Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial
      Description
      The first purpose is to evaluate the safety, effectiveness and tolerability (how well patients are able to take the study drug without serious side effects) of eslicarbazepine acetate (ESL) when given with levetiracetam or lamotrigine as a first option of treatment to those with partial-onset seizures who have not taken any previous treatments together for their partial-onset seizures. The second purpose of this research study is to evaluate the safety, effectiveness and tolerability (how well patients are able to take the study drug without serious side effects) of eslicarbazepine acetate (ESL) when taken in combination with a stable dose of 1-2 medications that have been taken for at least one month to those who have already been given combination treatments for their for partial-onset seizures in the past.
      Contact
      210-567-8222
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Human Innate Immunity and Tuberculosis
      Protocol No.
      HSC20170315H
      Official Title
      Human Innate Immunity and Tuberculosis
      Description
      Tuberculosis is an infection that primarily affects the lungs and causes fever and weight loss. While some people exposed to the tuberculosis (TB) bacteria develop the disease others do not. An important step in our understanding of these different responses is to measure the response of immune cells to infection with the TB bacteria. This study will request blood to be collected from healthy individuals and individuals who have had a positive test result for TB.
      Contact
      (210) 258-9577
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Improving and Sustaining Delivery of CPT for PTSD in Mental Health Systems
      Protocol No.
      HSC20160045H
      Official Title
      Improving and Sustaining Delivery of CPT for PTSD in Mental Health Systems
      Description
      The purpose of the study is to compare the impact of two strategies to sustain and improve the delivery of an evidence-based psychotherapy for PTSD, cognitive processing therapy (CPT).
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Ketamine for Antidepressant-Resistant PTSD
      Protocol No.
      HSC20150550H
      Official Title
      Ketamine for Antidepressant-Resistant PTSD
      Description
      The purpose of this study is to examine the effectiveness of repeated doses of ketamine in Veterans and active duty military personnel with treatment-resistant posttraumatic stress disorder (PTSD). This study consists of three treatment groups, and participation will last a total of 8-weeks. Eligible participants include veterans and active-duty military personnel with PTSD who are able to attend approximately 16 study visits at SAMMC.
      Contact
      210-539-9422
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Prospective, randomized, double blind controlled pilot study to compare...
      Protocol No.
      HSC20120196H
      Official Title
      Prospective, randomized, double blind controlled pilot study to compare topical voriconazole to placebo as a pain reducing agent at skin donor sites
      Description
      Primary 1. The pain levels for donor site wounds treated with voriconazole will be less than the pain levels for donor site wounds treated with placebo. 2. Cutaneous levels of oxidized linoleic acid metabolites (OLAMs) collected by microdialysis probes will be less in donor sites treated with topical voriconazole as compared to donor sites treated with placebo.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Variable-Length Cognitive Processing Therapy for Combat-Related PTSD
      Protocol No.
      HSC20140324H
      Official Title
      Variable-Length Cognitive Processing Therapy for Combat-Related PTSD
      Description
      This STRONG STAR research study will determine the most effective length of treatment for Posttraumatic Stress Disorder (PTSD) and to determine who will benefit from shorter or longer courses of treatment. Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD that involves learning to recognize and challenge thoughts related to traumatic experiences. The normal course of treatment is 12 sessions, but participants may be treated for up to 24 sessions or until PTSD symptoms have reduced significantly, whichever comes first. Eligible participants are active duty OIF/OEF/OND veterans with PTSD who are stationed at Fort Hood.
      Contact
      254-553-1871
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Reproductive Health

    •   Chlamydia Trachomatis Proteomics-Profiling Immune Responses in Women with...
      Protocol No.
      HSC20070236H
      Official Title
      Chlamydia Trachomatis Proteomics-Profiling Immune Responses in Women at Reproductive Age
      Description
      A research study looking at factors in the blood that may be related to infertility (difficulty in becoming pregnant). We want to learn if your body has ever created an immune response (made factors that can fight infection or cause swelling or scarring inside the body) to certain factors that may cause infertility.
      Contact
      210-567-4924
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Substance Abuse

    •   PRESCRIPTION OPIOID RESEARCH STUDY FOR RECREATIONAL DRUG USERS
      Protocol No.
      HSC20180167H
      Official Title
      REDUCING THE ABUSE LIABILITY OF PRESCRIPTION OPIOIDS IN RECREATIONAL DRUG USERS: A PILOT STUDY
      Description
      This is a study of new drug combinations to reduce the abuse potential of opioid analgesics amongst recreational drug users. At the UT Pain Clinic the effect of these drug combinations will be studied. Questions will be asked about how the drug affected you.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Urinary Tract and Kidney

    •   Assessment of Cognitive Function in Mexican Americans with End-Stage Renal...
      Protocol No.
      HSC20110429H
      Official Title
      Assessment of Cognitive Function in Mexican Americans with End-Stage Renal Disease Receiving Hemodialysis (ACME)
      Description
      The purpose of this study to explore the health-related quality of life and to evaluate cognitive function status in Mexican Americans who are on hemodialysis because they are diagnosed with end-stage renal disease (ESRD) due to type 2diabetes (T2D).
      Contact
      210-508-2889
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Urinary Stone Biorepository
      Protocol No.
      HSC20120213H
      Official Title
      Urinary Stone Biorepository
      Description
      We propose to create the Urinary Stone Biorepository for collection, storage and distribution of urinary stones and pertinent health information to use as a resource for future research examining areas such as novel methods of fragmenting kidney stones or the relationships between stone composition and clinical risk factors
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Women's Health

    •   Chemical and Environmental Intolerances
      Protocol No.
      HSC20150821H
      Official Title
      Toxicant Induced Loss of Tolerance: Research and Education
      Description
      The purpose of this research is to identify individuals who suffer from chemical intolerances and to look for potential environmental triggers that may be in their homes. Our goal is to offer practical solutions and determine if symptoms improve after implementing our team''s recommendations.
      Contact
      210-827-7681
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Chlamydia Trachomatis Proteomics-Profiling Immune Responses in Women with...
      Protocol No.
      HSC20070236H
      Official Title
      Chlamydia Trachomatis Proteomics-Profiling Immune Responses in Women at Reproductive Age
      Description
      A research study looking at factors in the blood that may be related to infertility (difficulty in becoming pregnant). We want to learn if your body has ever created an immune response (made factors that can fight infection or cause swelling or scarring inside the body) to certain factors that may cause infertility.
      Contact
      210-567-4924
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study...
      Protocol No.
      HSC20170199H
      Official Title
      Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study in idiopathic pulmonary fibrosis
      Description
      To reduce the abundance of pro-inflammatory cells over baseline within subjects following treatment with dasatinib and quercetin
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Wounds and Injuries

    •   Cognitive-Behavioral Therapy for Posttraumatic Headache
      Protocol No.
      HSC20140339H
      Official Title
      CAP - Consortium to Alleviate PTSD - STVHCS Project 7 entitled -Randomized Clinical Trial of Cognitive-Behavior Therapy for Posttraumatic Headache-
      Description
      This study will evaluate whether a leading cognitive behavioral therapy for migraine headaches is effective with posttraumatic headaches (PTHA) for those who also have symptoms of posttraumatic stress (PTS) or posttraumatic stress disorder (PTSD). Investigators also seek to determine if treatment for PTHA also alleviates symptoms of PTS/PTSD, and whether treatment for PTS/PTSD might also alleviate headache symptoms. Eligible participants are OIF/OEF/OND veterans with posttraumatic headache following a head injury and co-occurring symptoms of PTS/PTSD who reside in the San Antonio area.
      Contact
      210-562-6737
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Open Globe Injury Registry
      Protocol No.
      HSC20130270H
      Official Title
      Open Globe Injury Registry
      Description
      To learn about outcomes in open globe injuries. Open Globe Eye injury is defined as a traumatic breakdown in the integrity of the wall of the eye.
      Contact
      210-567-8409
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Study of Tranexamic Acid During Air Medical Prehospital Transport Trail.
      Protocol No.
      HSC20150290H
      Official Title
      Study of Tranexamic acid during Air and ground Medical Prehospital transport (STAAMP) trial Phase 3 Multi-Center, Prospective, Randomized, Blinded, Controlled Interventional Trial
      Description
      Patients that are 18 years of age and older that are involved in a very serious accident where they are suspected of bleeding badly on the outside or suspected of bleeding on the inside. Their blood pressure may be low. Patients suspected of this will automatically be enrolled in the study by the Airlife Nurses. Patients get randomized to get the study medication or a placebo. The study drug helps stop bleeding and the placebo is salt water. Once patients get to the hospital they continue in the study and will have the option then to decide to continue in the study of not.
      Contact
      210-743-4130
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   VA Polytrauma Rehabilitation Center (PRC) Traumatic Brain Injury Model...
      Protocol No.
      HSC20140208H
      Official Title
      VA Polytrauma Rehabilitation Center (PRC) Traumatic Brain Injury Model Systems (TBIMS) at the South Texas Veterans Health Care System - Audie Murphy PRC
      Description
      We are searching for interested Veterans and active service members to participate in a longitudinal study of the short and long-term outcomes related to traumatic brain injury. By understanding those outcomes we hope to improve the quality of life of individuals and families affected by TBI.
      Contact
      210-617-5300
      Locations
      UT Health Science Center
      Learn More About This Study